BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53. [PMID: 20525969 DOI: 10.1136/gut.2009.192757] [Cited by in Crossref: 631] [Cited by in F6Publishing: 693] [Article Influence: 52.6] [Reference Citation Analysis]
Number Citing Articles
1 Yu C, Qiu J, Xiong M, Ou C, Zeng M, Song H. Trends in Helicobacter pylori-related gastric ulcer research from 2012 to 2022: A bibliometric and visual analysis. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1027534] [Reference Citation Analysis]
2 Le Thi TG, Werkstetter K, Kotilea K, Bontems P, Cabral J, Cilleruelo Pascual ML, Kori M, Barrio J, Homan M, Kalach N, Lima R, Tavares M, Urruzuno P, Misak Z, Urbonas V, Koletzko S, Sykora J, Miele E, Krahl A, Klemenak M, Papadopoulou A, Chiaro A, Ugras MK, de Laffolie J, Matusiewics K, Rea F, Casswall T, Roma E, Banoub H, Cseh A, Rogalidou M, Lopes AI, for the Helicobacter pylori Special Interest Group of ESPGHAN. Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry. Infection 2022. [DOI: 10.1007/s15010-022-01948-y] [Reference Citation Analysis]
3 He X, Wang X, Huang X, Li D, Liu G, Wang W, Li D. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: a randomized trial. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.102052] [Reference Citation Analysis]
4 Karbalaei M, Keikha M, Talebi Bezmin Abadi A. Prevalence of Primary Multidrug-resistant Helicobacter pylori in Children: A Systematic Review and Meta-analysis. Arch Med Res 2022:S0188-4409(22)00101-1. [PMID: 36089418 DOI: 10.1016/j.arcmed.2022.08.010] [Reference Citation Analysis]
5 Han YY, Long H, Lin Y, He Q, Chen WG, Ding XW, Zhou L, An P, Wang F, Zhang ZY, Hu YL, Li PY. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study. Helicobacter 2022. [PMID: 35939559 DOI: 10.1111/hel.12922] [Reference Citation Analysis]
6 Kuo C, Ke J, Kuo T, Lin C, Hsieh S, Chiu Y, Wu H, Huang M, Bui N, Chiu C, Chiu C, Lai C. Multiple amino acid substitutions in penicillin-binding protein-1A confer amoxicillin resistance in refractory Helicobacter pylori infection. Journal of Microbiology, Immunology and Infection 2022. [DOI: 10.1016/j.jmii.2022.07.006] [Reference Citation Analysis]
7 Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. Helicobacter 2022;:e12918. [PMID: 35877765 DOI: 10.1111/hel.12918] [Reference Citation Analysis]
8 Shi X, Wang C, Meng F, Ma S, Xu G, Liu T, Guo X, Li H, Qi X. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgrad Med 2022. [PMID: 35860966 DOI: 10.1080/00325481.2022.2105094] [Reference Citation Analysis]
9 Li L, Bao B, Chai X, Chen X, Su X, Feng S, Zhu X. The Anti-Inflammatory Effect of Callicarpa nudiflora Extract on H. Pylori-Infected GES-1 Cells through the Inhibition of ROS/NLRP3/Caspase-1/IL-1β Signaling Axis. Canadian Journal of Infectious Diseases and Medical Microbiology 2022;2022:1-8. [DOI: 10.1155/2022/5469236] [Reference Citation Analysis]
10 Guo L, Zhang F, Wang S, Li R, Zhang L, Zhang Z, Yin R, Liu H, Liu K. Oral Immunization With a M Cell-Targeting Recombinant L. Lactis Vaccine LL-plSAM-FVpE Stimulate Protective Immunity Against H. Pylori in Mice. Front Immunol 2022;13:918160. [DOI: 10.3389/fimmu.2022.918160] [Reference Citation Analysis]
11 Zhang M, Pang M, Zhang M. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Clinics (Sao Paulo) 2022;77:100058. [PMID: 35810638 DOI: 10.1016/j.clinsp.2022.100058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Goldberg L, Amrick TJ. Successful Eradication of Helicobacter pylori with 5-Day Concomitant Treatment. GastroHep 2022;2022:1-4. [DOI: 10.1155/2022/1211329] [Reference Citation Analysis]
13 Niu M, Zhou Y, Xie Y, Li X, Tian Y, Yao L, Li X, Gao H, Bai F. Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori. Front Pharmacol 2022;13:771876. [PMID: 35571120 DOI: 10.3389/fphar.2022.771876] [Reference Citation Analysis]
14 Chen HF, Gong Y, Huang Z, Zhao G, Chen ZM, Zen YM, Li HZ, Hu YL. Efficacy and safety of Chinese herbal medicine Qirui Weishu capsule in treating chronic non-atrophic gastritis: A multicentre, double-blind, randomized controlled clinical trial. J Ethnopharmacol 2022;:115341. [PMID: 35551978 DOI: 10.1016/j.jep.2022.115341] [Reference Citation Analysis]
15 Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Lu N, Zhu Y. Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: A prospective, randomized clinical pilot study. Helicobacter. [DOI: 10.1111/hel.12896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Geng T, Yu ZS, Zhou XX, Liu B, Zhang HH, Li ZY. Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, China. Eur J Pediatr 2022. [PMID: 35469031 DOI: 10.1007/s00431-022-04456-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Huang Y, Li R, Dai Y, Qin C, He J, Yang S, Wang T, Su Y, Jia L, Zhao W. Rhamnolipid-assisted black phosphorus nanosheets with efficient isolinderalactone loading against drug resistant Helicobacter pylori. Materials & Design 2022;216:110536. [DOI: 10.1016/j.matdes.2022.110536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Nabavi-rad A, Azizi M, Jamshidizadeh S, Sadeghi A, Aghdaei HA, Yadegar A, Zali MR, Niedźwiedzka-rystwej P. The Effects of Vitamins and Micronutrients on Helicobacter pylori Pathogenicity, Survival, and Eradication: A Crosstalk between Micronutrients and Immune System. Journal of Immunology Research 2022;2022:1-22. [DOI: 10.1155/2022/4713684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Zhou BG, Yan XL, Wan LY, Zhang Q, Li B, Ai YW. Effect of enhanced patient instructions on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials. Helicobacter 2022;:e12869. [PMID: 35178810 DOI: 10.1111/hel.12869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jin F, Yang H. Transcriptome Analysis of the Response of Mature Helicobacter pylori Biofilm to Different Doses of Lactobacillus salivarius LN12 with Amoxicillin and Clarithromycin. Antibiotics 2022;11:262. [DOI: 10.3390/antibiotics11020262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Jha SK, Kumar R, Kumar A, Purkayastha S, Keshri R, Kumar S, Singh AV. Addition of Nitazoxanide to Standard Clarithromycin Based Triple Therapy for 2 Weeks Effectively Eradicates Treatment-Naive Helicobacter Pylori Infection. A Single Centre prospective, open-label study. Middle East J Dig Dis 2022;14:77-84. [DOI: 10.34172/mejdd.2022.259] [Reference Citation Analysis]
22 Helmbold L, Ghebremedhin B, Bellm A, Hopkins MA, Wirth S, Aydin M. Increased Antibiotic Resistance in Children with Helicobacter pylori Infection: A Retrospective Study. Pathogens 2022;11:178. [DOI: 10.3390/pathogens11020178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
24 Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. World J Clin Cases 2022; 10(1): 227-235 [DOI: 10.12998/wjcc.v10.i1.227] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Yang JC, Kao JY. Treatment considerations in Helicobacter pylori management. Aliment Pharmacol Ther 2022;55 Suppl 1:S22-8. [PMID: 34989432 DOI: 10.1111/apt.16652] [Reference Citation Analysis]
26 Huang JG, Lim SYS, Aw MM, Quak SH. Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort. Helicobacter 2021;:e12868. [PMID: 34958710 DOI: 10.1111/hel.12868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore) 2021;100:e28323. [PMID: 34941132 DOI: 10.1097/MD.0000000000028323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cho JH, Jin SY, Park S. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34883037 DOI: 10.1080/14787210.2022.2017280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Okoro RN, Abdullahi K, Dayar DA. Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria. Medicine Access @ Point of Care 2021;5:239920262110627. [DOI: 10.1177/23992026211062729] [Reference Citation Analysis]
30 Cheok YY, Lee CYQ, Cheong HC, Vadivelu J, Looi CY, Abdullah S, Wong WF. An Overview of Helicobacter pylori Survival Tactics in the Hostile Human Stomach Environment. Microorganisms 2021;9:2502. [PMID: 34946105 DOI: 10.3390/microorganisms9122502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
31 Zurita J, Sevillano G, Paz Y Miño A, Zurita-Salinas C, Peñaherrera V, Echeverría M, Navarrete H; Helicobacter pylori Research Group. Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population. J Appl Microbiol 2021. [PMID: 34856035 DOI: 10.1111/jam.15396] [Reference Citation Analysis]
32 Ghazvini K, Kamali H, Hosseininasab-nodoushan S, Keikha M. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021;25:101340. [DOI: 10.1016/j.genrep.2021.101340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Geerts H, van der Graaf P. Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease. ADR 2021;5:815-26. [DOI: 10.3233/adr-210039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ma Win TM, Htun M, Phyu Myint WP, Aung MM, Ni N. High‐dose dual therapy and CYP2C19 polymorphism in Helicobacter pylori eradication. GastroHep 2021;3:379-383. [DOI: 10.1002/ygh2.484] [Reference Citation Analysis]
36 Griffith DM, Li H, Werrett MV, Andrews PC, Sun H. Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles. Chem Soc Rev 2021;50:12037-69. [PMID: 34533144 DOI: 10.1039/d0cs00031k] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]
37 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
39 Öztürk K, Kurt Ö, Çelebi G, Şarlak H, Karakaya MF, Demirci H, Kılınç A, Uygun A. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020;31:234-8. [PMID: 32343235 DOI: 10.5152/tjg.2020.18974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
40 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
41 Keshavarzi S, Sepehrimanesh M, Mirzaei B, Kuhi Hossein Abadi O, Sardari Z, Sajjadpur MM, Dept. of Microbiology, Fars Sciences and Research Branch, Islamic Azad University, Shiraz, Iran, Dept. of Biology, University of Louisiana at Lafayette, Louisiana, USA, Dept. of Medical Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran, Central Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Antimicrobial Effects of Aqueous and Hydro-Alcoholic Plantago psyllium leaf extracts on the Experimental Infection of Helicobacter pylori in a Rat Model. J Adv Med Biomed Res 2021;29:317-323. [DOI: 10.30699/jambs.29.137.317] [Reference Citation Analysis]
42 Chen LW, Chang LC, Hua CC, Liu CJ, Chou TS, Lin CL, Chien RN. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. J Clin Med 2021;10:4352. [PMID: 34640370 DOI: 10.3390/jcm10194352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Hackett RJ, Preston SL. H.pylori, part II : management in an era of antibiotic resistance. Trends Urology & Men Health 2021;12:18-24. [DOI: 10.1002/tre.818] [Reference Citation Analysis]
44 Bonilla S, Bousvaros A, Cardini J, Estrella-pimentel L, Mitchell PD, Goldshine J, Hirsch R, Jonas M, Fox V. Lessons From a Quality Improvement Project to Standardize the Process of Gastric Biopsy Culture for Helicobacter pylori. JPGN Reports 2021;2:e116. [DOI: 10.1097/pg9.0000000000000116] [Reference Citation Analysis]
45 Choi YI, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Seo JY, Park DK. Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients. World J Gastroenterol 2021; 27(31): 5247-5258 [PMID: 34497448 DOI: 10.3748/wjg.v27.i31.5247] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol 2021;12:e00391. [PMID: 34397042 DOI: 10.14309/ctg.0000000000000391] [Reference Citation Analysis]
47 Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter 2021;:e12840. [PMID: 34390083 DOI: 10.1111/hel.12840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Cha B, Bang BW, Shin JB, Ko EJ, Ko W, Kwon KS, Shin YW, Suh YJ, Kim H. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area. Scand J Gastroenterol 2021;56:1017-22. [PMID: 34369255 DOI: 10.1080/00365521.2021.1948606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Sasaki Y, Abe Y, Shoji M, Mizumoto N, Takeda H, Oizumi H, Yaoita T, Sawada N, Yamagishi K, Saito E, Watanabe M, Ishizawa K, Konta T, Kayama T, Tsugane S, Ueno Y, Inoue M. Reliability of self-reported questionnaire for epidemiological investigation of Helicobacter pylori eradication in a population-based cohort study. Sci Rep 2021;11:15605. [PMID: 34341428 DOI: 10.1038/s41598-021-95124-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Jin F, Yang H. Effects of Lactobacillus salivarius LN12 in Combination with Amoxicillin and Clarithromycin on Helicobacter pylori Biofilm In Vitro. Microorganisms 2021;9:1611. [PMID: 34442690 DOI: 10.3390/microorganisms9081611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
51 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
52 Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut Liver 2021;15:528-36. [PMID: 33376228 DOI: 10.5009/gnl20225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Van Thieu H, Duc NM, Nghi BTD, Van Bach N, Khoi HH, Tien VNT, Bang MTL, Ngoc TLC. Antimicrobial Resistance and the Successful Eradication of Helicobacter pylori-Induced Gastroduodenal Ulcers in Vietnamese Children. Med Arch 2021;75:112-5. [PMID: 34219870 DOI: 10.5455/medarh.2021.75.112-115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Voidarou CC, Rozos G, Alexopoulos A, Plessas S, Mantzourani I, Stavropoulou E, Tzora A, Bezirtzoglou E. In Vitro Screening Potential Antibacterial Properties of the Greek Oregano Honey against Clinical Isolates of Helicobacter pylori. Foods 2021;10:1568. [PMID: 34359441 DOI: 10.3390/foods10071568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Kim JJE, Kocsmár I, Buzás GM, Szirtes I, Rusz O, Diczházi C, Szijártó A, Hritz I, Schaff Z, Kiss A, Kocsmár É, Lotz G. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. Pathol Oncol Res 2021;27:1609863. [PMID: 34267605 DOI: 10.3389/pore.2021.1609863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Attaran B, Salehi N, Ghadiri B, Esmaeili M, Kalateh S, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The penicillin binding protein 1A of Helicobacter pylori, its amoxicillin binding site and access routes. Gut Pathog 2021;13:43. [PMID: 34183046 DOI: 10.1186/s13099-021-00438-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, Vlachou E, Tsibouris P, Alexandrakis G. 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. J Clin Gastroenterol 2020;54:522-7. [PMID: 32028286 DOI: 10.1097/MCG.0000000000001328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
58 Pozdeeva AO, Pozdeev OK, Gulyaev PE, Valeeva YV, Savinova AN. Current development of <i>Helicobacter pylori</i> eradication protocols. Russian Journal of Infection and Immunity 2021;11:1037-1049. [DOI: 10.15789/2220-7619-cdo-1679] [Reference Citation Analysis]
59 Puah SM, Goh KL, Ng HK, Chua KH. Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study. PeerJ 2021;9:e11518. [PMID: 34178444 DOI: 10.7717/peerj.11518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Perkovic N, Mestrovic A, Bozic J, Ivelja MP, Vukovic J, Kardum G, Sundov Z, Tonkic M, Puljiz Z, Vukojevic K, Tonkic A. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J Pers Med 2021;11:534. [PMID: 34207870 DOI: 10.3390/jpm11060534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Kotilea K, Cadranel S, Salame A, Nguyen J, Mahler T, Miendje Deyi VY, Verset L, Bontems P. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter 2021;26:e12825. [PMID: 34101296 DOI: 10.1111/hel.12825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Lee JW, Kim SJ, Choi CW, Kim HJ, Kang DH, Kim HW, Park SB, Nam HS, Ryu DG. Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation. Medicine (Baltimore) 2021;100:e26133. [PMID: 34032763 DOI: 10.1097/MD.0000000000026133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Yang C, Liu L, Majaw JK, Liang L, Chen Y. Efficacy of Lactobacillus reuteri supplementation therapy for Helicobacter pylori eradication: A meta-analysis of randomised controlled trials. Medicine in Microecology 2021;8:100036. [DOI: 10.1016/j.medmic.2021.100036] [Reference Citation Analysis]
64 Gong M, Han Y, Wang X, Tao H, Meng F, Hou B, Sun BB, Wang G. Effect of Temperature on Metronidazole Resistance in Helicobacter pylori. Front Microbiol 2021;12:681911. [PMID: 34093508 DOI: 10.3389/fmicb.2021.681911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
65 Chen B, Li F, Zhu XK, Xie W, Hu X, Zan MH, Li X, Li QY, Guo SS, Zhao XZ, Jiang YA, Cao Z, Liu W. Highly biocompatible and recyclable biomimetic nanoparticles for antibiotic-resistant bacteria infection. Biomater Sci 2021;9:826-34. [PMID: 33215618 DOI: 10.1039/d0bm01397h] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
66 Gu SY, Cao XJ, Feng Y, Wei QQ, Liang JQ, Xie LM, Liu YL, Feng HY, Guo XG. Identification of hub genes and signaling pathways related to gastric cells infected by Helicobacter pylori. Microb Pathog 2021;156:104932. [PMID: 33964417 DOI: 10.1016/j.micpath.2021.104932] [Reference Citation Analysis]
67 Tokunaga K, Suzuki C, Hasegawa M, Fujimori I. Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan. Clinicoecon Outcomes Res 2021;13:241-50. [PMID: 33889000 DOI: 10.2147/CEOR.S297680] [Reference Citation Analysis]
68 Ullah H, Di Minno A, Santarcangelo C, Khan H, Xiao J, Arciola CR, Daglia M. Vegetable Extracts and Nutrients Useful in the Recovery from Helicobacter pylori Infection: A Systematic Review on Clinical Trials. Molecules 2021;26:2272. [PMID: 33919894 DOI: 10.3390/molecules26082272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
69 Yang L, Zou A, Wu H, Guo H, Zhang F, Zou B, Wang J. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. Biomed Res Int 2021;2021:6150628. [PMID: 33937401 DOI: 10.1155/2021/6150628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
70 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 31.0] [Reference Citation Analysis]
71 Basu N, Ghosh R. Recent chemical syntheses of bacteria related oligosaccharides using modern expeditious approaches. Carbohydr Res 2021;507:108295. [PMID: 34271477 DOI: 10.1016/j.carres.2021.108295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
73 Kim SE, Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M, Korean College of Helicobacter and Upper Gastrointesinal Research. A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:48-58. [DOI: 10.7704/kjhugr.2020.0052] [Reference Citation Analysis]
74 Koroleva PI, Kuzikov AV, Masamrekh RA, Filimonov DA, Dmitriev AV, Zaviyalova MG, Rikova SM, Shich EV, Makhova AA, Bulko TV, Gilep AA, Shumyantseva VV. Modeling of Drug-Drug Interactions between Omeprazole and Erythromycin in the Cytochrome P450-Dependent System In vitro. Biochem Moscow Suppl Ser B 2021;15:62-70. [DOI: 10.1134/s1990750821010030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Jeon JY, Kim SY, Moon SJ, Oh K, Lee J, Kim B, Song GS, Kim MG. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. Clin Ther 2021;43:722-34. [PMID: 33637332 DOI: 10.1016/j.clinthera.2021.01.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, Escudero FA, Ward ZJ, Yeh JM. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol 2021;50-51:101735. [PMID: 33975689 DOI: 10.1016/j.bpg.2021.101735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
77 Çakir Güney B, Düzenli T, Önal Y, Kaplan M, Tanoğlu A. Favorable effects of close telephone follow-up on Helicobacter pylori eradication success. Anatolian Current Medical Journal 2021;3:10-14. [DOI: 10.38053/acmj.865053] [Reference Citation Analysis]
78 Yue P, Zhong J, Huang J, Lan Z, Zhong S. The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24504. [PMID: 33530275 DOI: 10.1097/MD.0000000000024504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Huang LW, Li L. Siliankang combined with esomeprazole sodium for treatment of Helicobacter pylori-associated gastritis: Efficacy and influence on NF-κB signaling pathway. Shijie Huaren Xiaohua Zazhi 2021; 29(3): 131-137 [DOI: 10.11569/wcjd.v29.i3.131] [Reference Citation Analysis]
80 Ang TL, Ang D. Helicobacter pylori Treatment Strategies in Singapore. Gut Liver 2021;15:13-8. [PMID: 31875670 DOI: 10.5009/gnl19308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Crowley E, Hussey S. Helicobacter pylori in Childhood. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00027-x] [Reference Citation Analysis]
82 Mestrovic A, Perkovic N, Bozic J, Pavicic Ivelja M, Vukovic J, Kardum G, Puljiz Z, Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500. [PMID: 33378403 DOI: 10.1371/journal.pone.0244500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
83 Park JH, Kim D, Choe JW, Kim SY, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ, Lee SW. First-line Helicobacter pylori Eradication Rate of the 10-day Hybrid Therapy. Korean J Helicobacter Up Gastrointest Res 2020;20:300-5. [DOI: 10.7704/kjhugr.2020.0019] [Reference Citation Analysis]
84 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
85 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
86 Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
87 Zhang J, Guo J, Li D, Chen M, Liu J, Feng C, He Q, Zhao J, Zhang L, Chen J, Shi Y. The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study. Medicine (Baltimore) 2020;99:e22976. [PMID: 33157939 DOI: 10.1097/MD.0000000000022976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
88 Lee HA, Kim JY, Kim J, Nam B, Kim O. Anti-Helicobacter pylori activity of acomplex mixture of Lactobacillus paracasei HP7 including the extract of Perilla frutescens var. acuta and Glycyrrhiza glabra. Lab Anim Res 2020;36:40. [PMID: 33134159 DOI: 10.1186/s42826-020-00073-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
89 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
90 Huang T, Yang S, Tai W, Liang C, Kuo C, Yao C, Wu C, Kuo Y, Chou Y, Lee C, Wu K, Chuah S. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance. Biomedical Journal 2020. [DOI: 10.1016/j.bj.2020.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy. J Clin Gastroenterol 2021;55:865-8. [PMID: 33136782 DOI: 10.1097/MCG.0000000000001457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Wang J, Zhang Y, Zhu Y, Liu J, Chen Y, Cao X, Yang Y. Total Synthesis and Immunological Evaluation of the Tri- d - glycero - d - manno -heptose Antigen of the Lipopolysaccharide as a Vaccine Candidate against Helicobacter pylori. Org Lett 2020;22:8780-5. [DOI: 10.1021/acs.orglett.0c03105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
93 Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
94 Cao Y, Zheng Y, Niu J, Zhu C, Yang D, Rong F, Liu G. Efficacy of Banxia Xiexin decoction for chronic atrophic gastritis: A systematic review and meta-analysis. PLoS One 2020;15:e0241202. [PMID: 33108375 DOI: 10.1371/journal.pone.0241202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
95 Ji CR, Liu J, Li YY, Guo CG, Qu JY, Zhang Y, Zuo X. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020;10:e037375. [PMID: 33077561 DOI: 10.1136/bmjopen-2020-037375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
96 Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020;104:9891-905. [PMID: 33052519 DOI: 10.1007/s00253-020-10945-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 13.5] [Reference Citation Analysis]
97 Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line Helicobacter pylori infection eradication: A randomized trial. Helicobacter 2020;25. [DOI: 10.1111/hel.12762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
98 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
99 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
100 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
101 Li ZX, Ma JL, Guo Y, Liu WD, Li M, Zhang LF, Zhang Y, Zhou T, Zhang JY, Gao HE, Guo XY, Ye DM, Li WQ, You WC, Pan KF. Suppression of Helicobacter pylori infection by daily cranberry intake: A double-blind, randomized, placebo-controlled trial. J Gastroenterol Hepatol 2021;36:927-35. [PMID: 32783238 DOI: 10.1111/jgh.15212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
102 Zhao Y, Ren M, Wang X, Lu G, Lu X, Zhang D, He S. Telephone-Based Reeducation of Drug Administration for Helicobacterpylori Eradication: A Multicenter Randomized Controlled Study. Gastroenterol Res Pract 2020;2020:8972473. [PMID: 32802048 DOI: 10.1155/2020/8972473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, Lan CH. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937115. [PMID: 33110448 DOI: 10.1177/1756284820937115] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
104 Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study. J Clin Med 2020;9:E2410. [PMID: 32731455 DOI: 10.3390/jcm9082410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
105 Zhang M, Zhang C, Zhao J, Zhang H, Zhai Q, Chen W. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects. Microb Pathog 2020;147:104403. [PMID: 32707316 DOI: 10.1016/j.micpath.2020.104403] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
106 Fauzia KA, Miftahussurur M, Syam AF, Waskito LA, Doohan D, Rezkitha YAA, Matsumoto T, Tuan VP, Akada J, Yonezawa H, Kamiya S, Yamaoka Y. Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins (Basel) 2020;12:E473. [PMID: 32722296 DOI: 10.3390/toxins12080473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
107 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
108 Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, Wu KL, Hu TH, Chuah SK. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74:1718-1724. [PMID: 30768161 DOI: 10.1093/jac/dkz046] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 19.5] [Reference Citation Analysis]
109 Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J Gastroenterol 2020;55:969-76. [DOI: 10.1007/s00535-020-01709-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
110 Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. J Chemother 2020;32:273-85. [PMID: 32657237 DOI: 10.1080/1120009X.2020.1790889] [Reference Citation Analysis]
111 Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol 2020;20:218. [PMID: 32650737 DOI: 10.1186/s12876-020-01370-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
112 Jiang W, Qi J, Liao J, Wan Z, Liang W, Huang J, Cao Y, Xiao J, Yang X. Structural characterization of pectin-bismuth complexes and their aggregation in acidic conditions. International Journal of Biological Macromolecules 2020;154:788-94. [DOI: 10.1016/j.ijbiomac.2020.03.143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
113 Gong EJ, Ahn JY, Kim JM, Lee SM, Na HK, Lee JH, Jung KW, Choi KD, Kim DH, Song HJ, Lee GH, Kim SW, Jung HY. Genotypic and Phenotypic Resistance to Clarithromycin in Helicobacter pylori Strains. J Clin Med 2020;9:E1930. [PMID: 32575584 DOI: 10.3390/jcm9061930] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
114 Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714. [PMID: 32533599 DOI: 10.1111/hel.12714] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
115 Handa O, Naito Y, Osawa M, Murao T, Matsumoto H, Umegaki E, Shiotani A. Nutrients and probiotics: current trends in their use to eradicate Helicobacter pylori. J Clin Biochem Nutr 2020;67:26-8. [PMID: 32801465 DOI: 10.3164/jcbn.20-51] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
116 Sharara AI. Confirmatory Testing for Eradication of Helicobacter pylori: Challenges and Opportunities. Clin Gastroenterol Hepatol 2021;19:232-4. [PMID: 32492481 DOI: 10.1016/j.cgh.2020.05.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
117 Cho JH, Jin SY. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy. Expert Rev Gastroenterol Hepatol 2020;14:553-64. [PMID: 32410515 DOI: 10.1080/17474124.2020.1770594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
118 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Guo Y, Wei W, Chen JD. Effects and mechanisms of acupuncture and electroacupuncture for functional dyspepsia: A systematic review. World J Gastroenterol 2020; 26(19): 2440-2457 [PMID: 32476804 DOI: 10.3748/wjg.v26.i19.2440] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
120 Guo Y, Wei W, Chen JD. Effects and mechanisms of acupuncture and electroacupuncture for functional dyspepsia: A systematic review. WJG 2020;26:2439-56. [DOI: 10.3748/wjg.v26.i19.2439] [Reference Citation Analysis]
121 Horie R, Handa O, Ando T, Ose T, Murakami T, Suzuki N, Sendo R, Imamoto E, Itoh Y. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter 2020;25. [DOI: 10.1111/hel.12698] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
122 Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes 2020;11:1314-23. [PMID: 32362221 DOI: 10.1080/19490976.2020.1754118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
123 Fiorini G, Saracino IM, Zullo A, Pavoni M, Saccomanno L, Lazzarotto T, Cavallo R, Antonelli G, Vaira B. Antibiotic Resistance and Therapy for H. pylori Infection in Immigrant Patients Treated in Italy. J Clin Med 2020;9:E1299. [PMID: 32370005 DOI: 10.3390/jcm9051299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Borges AS, Minozzo BR, Santos H, Ardisson JS, Rodrigues RP, Romão W, Borges WDS, Gonçalves RDCR, Beltrame FL, Kitagawa RR. Plectranthus barbatus Andrews as anti-Helicobacter pylori agent with activity against adenocarcinoma gastric cells. Industrial Crops and Products 2020;146:112207. [DOI: 10.1016/j.indcrop.2020.112207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
125 Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
126 Howell AB, Wang L. Potential of cranberry for suppressing Helicobacter pylori, a risk factor for gastric cancer. JBR 2020;10:11-20. [DOI: 10.3233/jbr-180375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
127 Marcus EA, Tokhtaeva E, Jimenez JL, Wen Y, Naini BV, Heard AN, Kim S, Capri J, Cohn W, Whitelegge JP, Vagin O. Helicobacter pylori infection impairs chaperone-assisted maturation of Na-K-ATPase in gastric epithelium. Am J Physiol Gastrointest Liver Physiol 2020;318:G931-45. [PMID: 32174134 DOI: 10.1152/ajpgi.00266.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
128 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
129 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
130 Yin G, Bie S, Gu H, Shu X, Zheng W, Peng K, Zhao H, Li F, Chen B, Botchway BOA, Fang M, Jiang M. Application of gene chip technology in the diagnostic and drug resistance detection of Helicobacter pylori in children. J Gastroenterol Hepatol 2020;35:1331-9. [PMID: 31930581 DOI: 10.1111/jgh.14980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
131 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
132 Kornienko EA, Parolova NI, Ivanov SV, Polev DS, Zykin PA, Kondratenko YD, Zakharchenko MM. Gastric microbiota and probiotics opportunities in helicobacter pylori eradication in children. GHOA 2020;11:13-23. [DOI: 10.15406/ghoa.2020.11.00407] [Reference Citation Analysis]
133 Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol 2019;30:420-35. [PMID: 31060997 DOI: 10.5152/tjg.2019.18693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
134 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
135 Derbak MA, Dankanych YE, Ganich OT. POSSIBILITY OF HELICOBACTER PYLORI ERADICATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C. VPBM 2020;4:113. [DOI: 10.29254/2077-4214-2020-4-158-113-117] [Reference Citation Analysis]
136 Wang R, Li H, Ip TK, Sun H. Bismuth drugs as antimicrobial agents. Medicinal Chemistry 2020. [DOI: 10.1016/bs.adioch.2019.10.011] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
137 Yang J, Zhang Y, Fan L, Zhu YJ, Wang TY, Wang XW, Chen DF, Lan CH. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114:437-445. [PMID: 30807294 DOI: 10.14309/ajg.0000000000000132] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
138 Hanafy AS, Seleem WM. Refractory Helicobacter pylori gastritis: The hidden predictors of resistance. Journal of Global Antimicrobial Resistance 2019;19:194-200. [DOI: 10.1016/j.jgar.2019.05.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Rizvanov AA, Abadi ATB. Helicobacter pylori Infection and Vaccination: Current Standoff. BioNanoSci 2019;9:928-929. [DOI: 10.1007/s12668-019-00637-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A, Hritz I, Schaff Z, Rugge M, Fassan M, Kiss A, Lotz G. Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. Helicobacter 2020;25:e12670. [PMID: 31701608 DOI: 10.1111/hel.12670] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
141 Farina M, Brundu A, Bonferoni MC, Juliano C, Rassu G, Gavini E, Cerri G. Antibacterial activity of Na-clinoptilolite against Helicobacter pylori: in-vitro tests, synergistic effect with amoxicillin and stability of the antibiotic formulated with the zeolite. Microporous and Mesoporous Materials 2019;288:109592. [DOI: 10.1016/j.micromeso.2019.109592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
142 Epstein TD, Wu B, Moulton KD, Yan M, Dube DH. Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen Helicobacter pylori. ACS Infect Dis 2019;5:1682-7. [PMID: 31487153 DOI: 10.1021/acsinfecdis.9b00251] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
143 Olleik H, Baydoun E, Perrier J, Hijazi A, Raymond J, Manzoni M, Dupuis L, Pauleau G, Goudard Y, Villéon B, Goin G, Sockeel P, Choudhary MI, Pasquale ED, Nadeem-Ul-Haque M, Ali H, Khan AI, Shaheen F, Maresca M. Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori. Biomolecules 2019;9:E598. [PMID: 31614561 DOI: 10.3390/biom9100598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
144 Lv C, Jia F, Bai X, Wang D, Chen Y, Ding J, Fang L. Insights into the Suppression of Multidrug-Resistant Helicobacter pylori by Probiotics Supernatant. Jundishapur J Microbiol 2019;12. [DOI: 10.5812/jjm.91797] [Reference Citation Analysis]
145 Yu M, Zhang R, Ni P, Chen S, Duan G. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials. PLoS One 2019;14:e0223309. [PMID: 31577828 DOI: 10.1371/journal.pone.0223309] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
146 Yoon JY, Cha JM, Hong SS, Kim HK, Kwak MS, Jeon JW, Shin HP. Fermented milk containing Lactobacillus paracasei and Glycyrrhiza glabra has a beneficial effect in patients with Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore) 2019;98:e16601. [PMID: 31464895 DOI: 10.1097/MD.0000000000016601] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
147 Li Y, Zhang Y, Meng H, Liao M, Su Z, Zhai M, Jiang L, Li P, Ding X. Efficacy and safety of acupuncture therapy for chronic atrophic gastritis: A meta-analysis and trial sequential analysis protocol. Medicine (Baltimore) 2019;98:e17003. [PMID: 31464956 DOI: 10.1097/MD.0000000000017003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
148 Tai WC, Liang CM, Bi KW, Kuo CM, Lu LS, Wu CK, Yang SC, Kuo YH, Lee CH, Huang CF, Hsu CN, Hsu PI, Wu DC, Hu TH, Wu KL, Chuah SK. A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial. Infect Drug Resist 2019;12:2923-31. [PMID: 31571945 DOI: 10.2147/IDR.S213998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-5104 [PMID: 31558859 DOI: 10.3748/wjg.v25.i34.5097] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
150 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
151 Ong S, Kim SE, Kim JH, Yi NH, Kim TY, Jung K, Park MI, Jung HY. Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial. Helicobacter. 2019;24:e12654. [PMID: 31411793 DOI: 10.1111/hel.12654] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
152 Zhou B, Chen L, Li B, Wan L, Ai Y. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis. Helicobacter 2019;24. [DOI: 10.1111/hel.12651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
153 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
154 Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol 2019;19:132. [PMID: 31345165 DOI: 10.1186/s12876-019-1056-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
155 Fernández-Reyes M, Tamayo E, Rojas-Rengifo D, Fischer W, Carrasco-García E, Alonso M, Lizasoain J, Bujanda L, Cosme Á, Montes M. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain. Eur J Clin Invest 2019;49:e13150. [PMID: 31192451 DOI: 10.1111/eci.13150] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
156 Delchier JC, Bastuji-Garin S, Raymond J, Megraud F, Amiot A, Cambau E, Burucoa C;  HELICOSTIC Study Group. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492-499. [PMID: 31257067 DOI: 10.1016/j.medmal.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
157 Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of Vonoprazan for Helicobacter pylori Eradication. Intern Med 2020;59:153-61. [PMID: 31243237 DOI: 10.2169/internalmedicine.2521-18] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
158 Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N. Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure. J Clin Microbiol. 2019;57:pii: e01834-18. [PMID: 31068413 DOI: 10.1128/jcm.01834-18] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
159 Li H, Yang T, Tang H, Tang X, Shen Y, Benghezal M, Tay A, Marshall B. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed. Precision Clinical Medicine 2019;2:77-80. [DOI: 10.1093/pcmedi/pbz009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
160 Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, Resnick MB, Moss SF. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA. Dig Dis Sci. 2019;64:2893-2898. [PMID: 31187323 DOI: 10.1007/s10620-019-05694-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
161 Gebeyehu E, Nigatu D, Engidawork E. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study. PLoS One 2019;14:e0217645. [PMID: 31163069 DOI: 10.1371/journal.pone.0217645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
162 Huang Y, Hang X, Jiang X, Zeng L, Jia J, Xie Y, Li F, Bi H. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori. Antimicrob Agents Chemother. 2019;63. [PMID: 30936098 DOI: 10.1128/aac.00004-19] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
163 Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
164 Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, Suzuki H, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019;24:e12597. [PMID: 31111585 DOI: 10.1111/hel.12597] [Cited by in Crossref: 86] [Cited by in F6Publishing: 98] [Article Influence: 28.7] [Reference Citation Analysis]
165 Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int 2019;2019:9781212. [PMID: 31211144 DOI: 10.1155/2019/9781212] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
166 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
167 Kwon YH, Jeon SW, Nam SY, Lee HS, Park JH. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019;24:e12585. [PMID: 30969459 DOI: 10.1111/hel.12585] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
168 Yan W, Gu L, Ren W, Ma X, Qin M, Lyu M, Wang S. Recognition of Helicobacter pylori by protein-targeting aptamers. Helicobacter 2019;24:e12577. [PMID: 30950149 DOI: 10.1111/hel.12577] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
169 Silva KMMN, de Carvalho DÉL, Valente VMM, Campos Rubio JC, Faria PE, Silva-caldeira PP. Concomitant and controlled release of furazolidone and bismuth(III) incorporated in a cross-linked sodium alginate-carboxymethyl cellulose hydrogel. International Journal of Biological Macromolecules 2019;126:359-66. [DOI: 10.1016/j.ijbiomac.2018.12.136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
170 Wang T, Yang X, Li Y, Li L, Liu J, Ji C, Sun Y, Li Y, Zuo X. Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study. Helicobacter. 2019;24:e12569. [PMID: 30848868 DOI: 10.1111/hel.12569] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
171 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019;34:666-72. [DOI: 10.1111/jgh.14625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
172 Yi DM, Yang TT, Chao SH, Li YX, Zhou YL, Zhang HH, Lan L, Zhang YW, Wang XM, Zhang YR, Li J, Ding SZ. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore) 2019;98:e14408. [PMID: 30732192 DOI: 10.1097/MD.0000000000014408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
173 Miftahussurur M, Aftab H, Shrestha PK, Sharma RP, Subsomwong P, Waskito LA, Doohan D, Fauzia KA, Yamaoka Y. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control 2019;8:40. [PMID: 30815255 DOI: 10.1186/s13756-019-0482-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
174 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
175 Fontes LES, Martimbianco ALC, Zanin C, Riera R. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2019;2:CD012357. [PMID: 30746681 DOI: 10.1002/14651858.cd012357.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
176 Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK, Gareayaghi N, Ergin S, Erzin YZ, Bal K, Tascı İ, Tokman HB. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol 2019;68:566-73. [PMID: 30724729 DOI: 10.1099/jmm.0.000944] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
177 Asgari B, Kermanian F, Derakhshan N, Asna-Ashari M, Sadat ZRN, Yaslianifard S. HONEY-DERIVED LACTOBACILLUS RHAMNOSUS ALLEVIATES HELICOBACTER PYLORI-INDUCED GASTRO-INTESTINAL INFECTION AND GASTRIC INFLAMMATION IN C57BL/6 MICE: AN IMMUNO-HISTOLOGIC STUDY. Arq Gastroenterol 2018;55:279-82. [PMID: 30540092 DOI: 10.1590/S0004-2803.201800000-70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
178 Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, Kim JM, Lee DH, Jung HC. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. [PMID: 30632237 DOI: 10.1111/hel.12561] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
179 Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy. Korean J Gastroenterol 2019;73:26. [DOI: 10.4166/kjg.2019.73.1.26] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
180 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Medicina Clínica (English Edition) 2019;152:65-71. [DOI: 10.1016/j.medcle.2018.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Hong SS, Lee HA, Kim JY, Jeong JW, Shim JJ, Lee JL, Sim JH, Chung Y, Kim O. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacilllus paracasei HP7. Lab Anim Res 2018;34:216-22. [PMID: 30671108 DOI: 10.5625/lar.2018.34.4.216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
182 Cerqueira RM, Correia M, Vilar H, Manso MC. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. Obes Surg 2018;28:743-7. [PMID: 29076008 DOI: 10.1007/s11695-017-2915-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
183 Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutr 2018;4:48. [PMID: 32153909 DOI: 10.1186/s40795-018-0257-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
184 . Late breaking abstracts. United European Gastroenterol j 2018;6:1586-97. [DOI: 10.1177/2050640618812015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
185 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
186 Cosme A, Torrente Iranzo S, Montes Ros M, Fernández-reyes Silvestre M, Alonso Galán H, Lizasoain J, Bujanda L. Helicobacterpylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies: XXXX. Helicobacter 2019;24:e12557. [DOI: 10.1111/hel.12557] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
187 Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials.Eur J Pediatr. 2019;178:7-16. [PMID: 30446816 DOI: 10.1007/s00431-018-3282-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
188 Prudent E, Raoult D. Fluorescence in situ hybridization, a complementary molecular tool for the clinical diagnosis of infectious diseases by intracellular and fastidious bacteria. FEMS Microbiology Reviews 2018;43:88-107. [DOI: 10.1093/femsre/fuy040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
189 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:65-71. [PMID: 30424932 DOI: 10.1016/j.medcli.2018.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
190 Leow AH, Azmi AN, Loke M, Vadivelu J, Graham DY, Goh K. Optimizing first line 7‐day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis 2018;19:674-7. [DOI: 10.1111/1751-2980.12679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
191 Ntatsopoulos V, Macegoniuk K, Mucha A, Vassiliou S, Berlicki Ł. Structural exploration of cinnamate-based phosphonic acids as inhibitors of bacterial ureases. European Journal of Medicinal Chemistry 2018;159:307-16. [DOI: 10.1016/j.ejmech.2018.09.074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
192 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
193 Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Dekhnich N, Ivanchik N, Kozlov R, Alimov A, Steshits A, Kirsov P, Pandav K. Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation. Helicobacter 2018;23:e12545. [PMID: 30324756 DOI: 10.1111/hel.12545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
195 Gotoda T, Takano C, Kusano C, Suzuki S, Ikehara H, Hayakawa S, Andoh A. Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers. Helicobacter. 2018;23:e12541. [PMID: 30311721 DOI: 10.1111/hel.12541] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
196 Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67. [PMID: 30169908 DOI: 10.1111/jgh.14462] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
197 Hamza D, Elhelw R, Elhariri M, Ragab E. Genotyping and antimicrobial resistance patterns of Helicobacter pylori in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance. Microbial Pathogenesis 2018;123:330-8. [DOI: 10.1016/j.micpath.2018.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
198 Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34:686-692. [PMID: 30151994 DOI: 10.1111/jgh.14456] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
199 Siavoshi F, Saniee P, Malekzadeh R. Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori. Helicobacter 2018;23:e12531. [PMID: 30230637 DOI: 10.1111/hel.12531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
200 Talebi Bezmin Abadi A, Kusters JG. Future of Helicobacter pylori and its feasibility. Expert Review of Anti-infective Therapy 2018;16:733-5. [DOI: 10.1080/14787210.2018.1523715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Yang‐ou Y, Hu Y, Zhu Y, Lu N. The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta‐analysis. Helicobacter 2018;23. [DOI: 10.1111/hel.12535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
202 Hajiani E, Alavinejad P, Avandi N, Masjedizadeh AR, Shayesteh AA. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis 2018;10:242-8. [PMID: 31049172 DOI: 10.15171/mejdd.2018.117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
203 Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
204 Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N; the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. Antimicrob Agents Chemother 2018;62:e00432-18. [PMID: 29914954 DOI: 10.1128/AAC.00432-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
205 Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;84:310-318. [PMID: 28388387 DOI: 10.3949/ccjm.84a.14110] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
206 Silva GM, Silva HM, Nascimento J, Gonçalves J, Pereira F, Lima R. Helicobacter pylori antimicrobial resistance in a pediatric population. Helicobacter 2018;23:e12528. [DOI: 10.1111/hel.12528] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
207 Ye JF, Hong JB, Zhu Y, Xie Y, Shu X, Luo LY, Xie C, Zhu ZH, Lu NH. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. J Dig Dis 2017;18:704-8. [PMID: 29119724 DOI: 10.1111/1751-2980.12559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
208 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol. 2019;34:700-706. [PMID: 30011083 DOI: 10.1111/jgh.14383] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
209 Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018;24:334-344. [PMID: 29739175 DOI: 10.5056/jnm18029] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 12.0] [Reference Citation Analysis]
210 Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PLoS One 2018;13:e0197096. [PMID: 29889843 DOI: 10.1371/journal.pone.0197096] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
211 Blümel B, Goelz H, Kist M, Glocker E. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 2018;23:e12494. [DOI: 10.1111/hel.12494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
212 Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23:e12495. [PMID: 29873436 DOI: 10.1111/hel.12495] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
213 Kotilea K, Kalach N, Homan M, Bontems P. Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies. Paediatr Drugs 2018;20:337-51. [PMID: 29785564 DOI: 10.1007/s40272-018-0296-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
214 Chung JW, Kim SY, Park HJ, Chung CS, Lee HW, Lee SM, Kim I, Pak JH, Lee GH, Jeong JY. In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains. Gut Liver. 2017;11:648-654. [PMID: 28750485 DOI: 10.5009/gnl16503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
215 Bachir M, Allem R, Benejat L, Tifrit A, Medjekane M, Drici AE, Megraud F, Douidi KT. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. Journal of Antimicrobial Chemotherapy 2018;73:2034-8. [DOI: 10.1093/jac/dky167] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
216 Rego YF, Queiroz MP, Brito TO, Carvalho PG, de Queiroz VT, de Fátima Â, Macedo F Jr. A review on the development of urease inhibitors as antimicrobial agents against pathogenic bacteria. J Adv Res 2018;13:69-100. [PMID: 30094084 DOI: 10.1016/j.jare.2018.05.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
217 Cardoso O, Donato MM, Luxo C, Almeida N, Liberal J, Figueirinha A, Batista MT. Anti- Helicobacter pylori potential of Agrimonia eupatoria L. and Fragaria vesca. Journal of Functional Foods 2018;44:299-303. [DOI: 10.1016/j.jff.2018.03.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
218 Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23:e12485. [DOI: 10.1111/hel.12485] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
219 Kim J, Kim K, Lee JS, Kim SY, Kim KO, Kim YJ, Kwon KA, Park DK, Chung JW. [The Efficacy of Rebamipide or Ecabet Sodium Supplementation for Helicobacter pylori Eradication Therapy Compared with Quadruple (Concomitant) Regimen]. Korean J Gastroenterol 2018;71:204-12. [PMID: 29684969 DOI: 10.4166/kjg.2018.71.4.204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
220 Kashani N, Talebi Bezmin Abadi A. Comment on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin". Gastroenterol Res Pract 2018;2018:5173904. [PMID: 29676395 DOI: 10.1155/2018/5173904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
221 Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:4817-27. [DOI: 10.1007/s00253-018-8982-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
222 Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, Calvet X. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488. [PMID: 29663581 DOI: 10.1111/hel.12488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
223 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. Gastroenterología y Hepatología (English Edition) 2018;41:272-280. [DOI: 10.1016/j.gastre.2018.04.018] [Reference Citation Analysis]
224 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2018;41:272-80. [DOI: 10.1016/j.gastrohep.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
225 Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018;73:1681-7. [DOI: 10.1093/jac/dky056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
226 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
227 Shu X, Yin G, Liu M, Peng K, Zhao H, Jiang M. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. Helicobacter. 2018;23:e12481. [PMID: 29528162 DOI: 10.1111/hel.12481] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
228 Brennan DE, Dowd C, O’Morain C, McNamara D, Smith SM. Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection? World J Gastroenterol 2018; 24(9): 971-981 [PMID: 29531461 DOI: 10.3748/wjg.v24.i9.971] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
229 Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. [PMID: 29512258 DOI: 10.1111/hel.12475] [Cited by in Crossref: 172] [Cited by in F6Publishing: 181] [Article Influence: 43.0] [Reference Citation Analysis]
230 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. Gastroenterología y Hepatología (English Edition) 2018;41:145-152. [DOI: 10.1016/j.gastre.2018.03.004] [Reference Citation Analysis]
231 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
232 Zhang J, Zhong J, Ding J, Shi J, Tang T, Liu Q, Huang H, Dai L, Yang N. Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. J Glob Antimicrob Resist 2018;13:174-9. [PMID: 29444465 DOI: 10.1016/j.jgar.2017.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
233 Li L, Meng F, Zhu S, Guo S, Wang Y, Zhao X, Sun Y, Zhang Y, Wang Q, Xu H, Zhang S. Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori. Evid Based Complement Alternat Med. 2018;2018:4320219. [PMID: 29636776 DOI: 10.1155/2018/4320219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
234 Xinjie Y, Yan L. Effect of modified Sanhuang Xiexin Tang plus additional herbs combined with “standard triple therapy” on Helicobacter pylori eradication. Journal of Traditional Chinese Medicine 2018;38:101-6. [DOI: 10.1016/j.jtcm.2018.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
235 Choe JW, Jung SW, Kim SY, Hyun JJ, Jung YK, Koo JS, Yim HJ, Lee SW. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter. 2018;23:e12466. [PMID: 29369454 DOI: 10.1111/hel.12466] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
236 Dekhnich NN, Ivanchik NV, Kozlov RS, Alimov A, Steshits A, Kirsov P. Antimicrobial resistance of Helicobacter pylori in Smolensk. CMAC 2018;20:42-48. [DOI: 10.36488/cmac.2018.1.42-48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Lee SJ, Lim YJ, Hong SB, Nam JH, Jang DK, Kang HW, Kim JH, Lee JK, Koh M, Lee JH. Standard First-line Triple Therapy for Helicobacter pylori Infection: A Comparison of Eradication Rates Based on Timing of Administration of Proton Pump Inhibitors. Korean J Helicobacter Up Gastrointest Res 2018;18:115. [DOI: 10.7704/kjhugr.2018.18.2.115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
238 Dekhnich NN, Ivanchik NV, Kozlov RS. Comparison of in vitro activity of various macrolides against Helicobacter pylori. CMAC 2018;20:192-7. [DOI: 10.36488//cmac.2018.3.192-197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M; ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991-1003. [PMID: 28541262 DOI: 10.1097/MPG.0000000000001594] [Cited by in Crossref: 204] [Cited by in F6Publishing: 222] [Article Influence: 40.8] [Reference Citation Analysis]
240 Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018;23:e12456. [PMID: 29271026 DOI: 10.1111/hel.12456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
241 Tepes B, Kastelic M, Vujasinovic M, Lampic P, Seruga M, Jurecic NB, Nyssen OP, Donday MG, O'Morain C, Megraud F, McNicholl AG, Gisbert JP. Helicobacter Pylori Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on Helicobacter Pylori Management. Radiol Oncol 2018;52:1-6. [PMID: 29520199 DOI: 10.1515/raon-2017-0055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
242 Ramas M, Donday MG, Mcnicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterología y Hepatología (English Edition) 2017;40:658-662. [DOI: 10.1016/j.gastre.2017.05.010] [Reference Citation Analysis]
243 Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
244 Wahid SUH. Structural and functional characterization of the Helicobacter pylori cytidine 5'-monophosphate-pseudaminic acid synthase PseF: molecular insight into substrate recognition and catalysis mechanism. Adv Appl Bioinform Chem 2017;10:79-88. [PMID: 29062238 DOI: 10.2147/AABC.S139773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
245 Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
246 Redondo JJ, Keller PM, Zbinden R, Wagner K. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. Diagn Microbiol Infect Dis. 2018;90:1-6. [PMID: 29111147 DOI: 10.1016/j.diagmicrobio.2017.09.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
247 Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East J Dig Dis 2018;10:5-17. [PMID: 29682242 DOI: 10.15171/mejdd.2017.84] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
248 Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22. [PMID: 28940815 DOI: 10.1111/hel.12441] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
249 Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2017;32:589-594. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
250 Macías-garcía F, Llovo-taboada J, Díaz-lópez M, Bastón-rey I, Domínguez-muñoz JE. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter 2017;22:e12440. [DOI: 10.1111/hel.12440] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
251 Kwon YH, Kim JY, Kim N, Park JH, Nam RH, Lee SM, Kim JW, Kim JM, Park JY, Lee DH. Specific mutations of penicillin-binding protein 1A in 77 clinically acquired amoxicillin-resistant Helicobacter pylori strains in comparison with 77 amoxicillin-susceptible strains. Helicobacter 2017;22. [PMID: 28840971 DOI: 10.1111/hel.12437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
252 Gao CP, Zhou Z, Wang JZ, Han SX, Li LP, Lu H. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis. 2016;17:811-819. [PMID: 27977071 DOI: 10.1111/1751-2980.12432] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
253 Guo L, Yang H, Tang F, Yin R, Liu H, Gong X, Wei J, Zhang Y, Xu G, Liu K. Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on H. pylori Infection in Mongolian gerbils. Front Cell Infect Microbiol 2017;7:349. [PMID: 28824883 DOI: 10.3389/fcimb.2017.00349] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
254 Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterol Hepatol 2017;40:658-62. [PMID: 28780968 DOI: 10.1016/j.gastrohep.2017.05.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
255 Mathias F, Kabri Y, Okdah L, Di Giorgio C, Rolain JM, Spitz C, Crozet MD, Vanelle P. An Efficient One-Pot Catalyzed Synthesis of 2,4-Disubstituted 5-Nitroimidazoles Displaying Antiparasitic and Antibacterial Activities. Molecules 2017;22:E1278. [PMID: 28771219 DOI: 10.3390/molecules22081278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
256 Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología (English Edition) 2017;40:447-454. [DOI: 10.1016/j.gastre.2017.07.007] [Reference Citation Analysis]
257 Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología 2017;40:447-54. [DOI: 10.1016/j.gastrohep.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
258 Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017;11:2209-20. [PMID: 28814829 DOI: 10.2147/DDDT.S136240] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
259 Kim JS, Kim BW, Hong SJ, Kim JI, Shim KN, Kim JH, Baik GH, Kim SW, Song HJ, Kim JH. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. Gut Liver. 2016; Apr 28. [Epub ahead of print]. [PMID: 27114421 DOI: 10.5009/gnl15470] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
260 Hsu PI, Tsai FW, Kao SS, Hsu WH, Cheng JS, Peng NJ, Tsai KW, Hu HM, Wang YK, Chuah SK, Chen A, Wu DC. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017;112:1374-1381. [PMID: 28719592 DOI: 10.1038/ajg.2017.195] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
261 Wu MC, Wang YK, Liu CJ, Yu FJ, Kuo FC, Liu ML, Kuo CH, Wu DC, Huang YK, Wu IC. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol Res Pract 2017;2017:5320180. [PMID: 28791044 DOI: 10.1155/2017/5320180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
262 Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother 2017;18:1145-52. [PMID: 28657473 DOI: 10.1080/14656566.2017.1346087] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
263 Shimoyama T, Chinda D, Sawada Y, Komai K, Chiba H, Saito Y, Sasaki Y, Matsuzaka M, Fukuda S. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. Intern Med 2017;56:1621-7. [PMID: 28674348 DOI: 10.2169/internalmedicine.56.7823] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
264 Sapmaz F, Kalkan IH, Atasoy P, Basyigit S, Guliter S. A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. American Journal of Therapeutics 2017;24:e393-8. [DOI: 10.1097/mjt.0000000000000316] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
265 Debowski AW, Walton SM, Chua EG, Tay AC, Liao T, Lamichhane B, Himbeck R, Stubbs KA, Marshall BJ, Fulurija A, Benghezal M. Helicobacter pylori gene silencing in vivo demonstrates urease is essential for chronic infection. PLoS Pathog 2017;13:e1006464. [PMID: 28644872 DOI: 10.1371/journal.ppat.1006464] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
266 Rhodes LA PharmD. Practical considerations for managing Helicobacter pylori in college health. J Am Coll Health 2017;65:361-2. [PMID: 28622096 DOI: 10.1080/07448481.2017.1341901] [Reference Citation Analysis]
267 Fang WJ, Zhang XY, Yang B, Sui SJ, Chen M, Pan WH, Liao WQ, Zhong M, Wang QC. CHINESE HERBAL DECOCTION AS A COMPLEMENTARY THERAPY FOR ATROPHIC GASTRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Afr J Tradit Complement Altern Med 2017;14:297-319. [PMID: 28638893 DOI: 10.21010/ajtcam.v14i4.33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
268 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373-379. [PMID: 28655973 DOI: 10.20524/aog.2017.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
269 Acosta CP, Quiroga AJ, Sierra CH, Trespalacios AA. [Frequency of Helicobacter pylori nitroreductase RdxA mutations for metronidazole activation in a population in the Cauca Department, Colombia]. Biomedica 2017;37:191-9. [PMID: 28527283 DOI: 10.7705/biomedica.v37i2.3007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
270 Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017;18:62-7. [DOI: 10.1016/j.ajg.2017.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
271 Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, Song ZQ, Zou QH. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathog 2017;109:156-61. [PMID: 28552806 DOI: 10.1016/j.micpath.2017.05.035] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
272 Peng X, Song Z, He L, Lin S, Gong Y, Sun L, Zhao F, Gu Y, You Y, Zhou L, Zhang J. Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach. Int J Med Sci. 2017;14:595-601. [PMID: 28638276 DOI: 10.7150/ijms.18996] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
273 Zhang X, Jiang A, Wang G, Yu H, Qi B, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Fusion expression of the PGLa-AM1 with native structure and evaluation of its anti-Helicobacter pylori activity. Appl Microbiol Biotechnol 2017;101:5667-75. [DOI: 10.1007/s00253-017-8302-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
274 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 68] [Cited by in F6Publishing: 75] [Article Influence: 13.6] [Reference Citation Analysis]
275 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
276 Li Y, Sun Y, Wang W. Fractional order dynamics for clarithromycin against helicobacter pylori. 2017 6th Data Driven Control and Learning Systems (DDCLS) 2017. [DOI: 10.1109/ddcls.2017.8068152] [Reference Citation Analysis]
277 Gunnarsdottir AI, Gudjonsson H, Hardardottir H, Jonsdottir KD, Bjornsson ES. Antibiotic susceptibility of Helicobacter pylori in Iceland. Infect Dis (Lond) 2017;49:647-54. [PMID: 28440099 DOI: 10.1080/23744235.2017.1317359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
278 Das R, Sureshkumar S, Sreenath GS, Kate V. Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: A randomized trial. Saudi J Gastroenterol 2016;22:309-15. [PMID: 27488326 DOI: 10.4103/1319-3767.187605] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
279 Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Dig Dis Sci 2017;62:1580-9. [DOI: 10.1007/s10620-017-4564-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
280 Chunlertlith K, Limpapanasit U, Mairiang P, Vannaprasaht S, Tassaneeyakul W, Sangchan A, Sawadpanich K, Suttichaimongkol T, Pongpit J, Pattarapongsin M. Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication. Asian Pac J Cancer Prev 2017;18:927-32. [PMID: 28545189 DOI: 10.22034/APJCP.2017.18.4.927] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
281 Tamayo E, Montes M, Fernández-Reyes M, Lizasoain J, Ibarra B, Mendarte U, Zapata E, Mendiola J, Pérez-Trallero E. Clarithromycin resistance in Helicobacter pylori and its molecular determinants in Northern Spain, 2013-2015. J Glob Antimicrob Resist 2017;9:43-6. [PMID: 28343971 DOI: 10.1016/j.jgar.2016.12.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
282 Hu Y, Zhu Y, Lu NH. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62:1146-1154. [PMID: 28315035 DOI: 10.1007/s10620-017-4536-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 11.6] [Reference Citation Analysis]
283 Kotilea K, Mekhael J, Salame A, Mahler T, Miendje-Deyi VY, Cadranel S, Bontems P. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22. [PMID: 28303625 DOI: 10.1111/hel.12383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
284 Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infect Drug Resist 2017;10:85-90. [PMID: 28331349 DOI: 10.2147/IDR.S123798] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
285 Mansour-Ghanaei F, Pedarpour Z, Shafaghi A, Joukar F. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication. Middle East J Dig Dis. 2017;9:100-106. [PMID: 28638586 DOI: 10.15171/mejdd.2017.58] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
286 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
287 Serrano CA, Leon MA, Palma C, Vera M, Hernandez C, Harris PR. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. Journal of Pediatric Gastroenterology & Nutrition 2017;64:e56-60. [DOI: 10.1097/mpg.0000000000001257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
288 Branquinho D, Almeida N, Gregório C, Cabral JE, Casela A, Donato MM, Tomé L. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? BMC Gastroenterol 2017;17:31. [PMID: 28202013 DOI: 10.1186/s12876-017-0589-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
289 Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
290 Song ZQ, Liu J, Zhou LY. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin Med J (Engl). 2016;129:992-999. [PMID: 27064046 DOI: 10.4103/0366-6999.179803] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
291 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
292 Ashokkumar S, Agrawal S, Mandal J, Sureshkumar S, Sreenath GS, Kate V. Hybrid Therapy versus Sequential Therapy for Eradication of Helicobacter pylori: A Randomized Controlled Trial. J Pharmacol Pharmacother 2017;8:62-7. [PMID: 28706400 DOI: 10.4103/jpp.JPP_24_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
293 Park HY, Kang EJ, Kim DG, Kim KJ, Choi JW, Nam SY, Kwon YH, Lee HS, Jeon SW. High and Frequent Dose of Dexlansoprazole and Amoxicillin Dual Therapy for Helicobacter pylori Infections: A Single Arm Prospective Study. Korean J Gastroenterol 2017;70:176. [DOI: 10.4166/kjg.2017.70.4.176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
294 Jung YD, Kim Y, Chung WC. A Pilot Study of Helicobacter pylori Eradication Using a Polymerase Chain Reaction-based Test for Clarithromycin Resistance. Korean J Helicobacter Up Gastrointest Res 2017;17:200. [DOI: 10.7704/kjhugr.2017.17.4.200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
295 Miura M, Ohtaka M, Hanawa M, Shimura N, Yoda Y, Suzuki S. Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for &lt;i&gt;Helicobacter pylori&lt;/i&gt;. OJGas 2017;07:243-259. [DOI: 10.4236/ojgas.2017.79026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Kim GH. Status ofHelicobacter pyloriEradication in Japan. Korean J Helicobacter Up Gastrointest Res 2017;17:4. [DOI: 10.7704/kjhugr.2017.17.1.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
297 Watson E, Tatara AM, Kontoyiannis DP, Mikos AG. Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. ACS Biomater Sci Eng 2017;3:1207-20. [PMID: 33440510 DOI: 10.1021/acsbiomaterials.6b00501] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
298 Hanafi A, Lee WC, Loke MF, Teh X, Shaari A, Dinarvand M, Lehours P, Mégraud F, Leow AH, Vadivelu J, Goh KL. Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant Helicobacter pylori. Front Microbiol 2016;7:2015. [PMID: 28018334 DOI: 10.3389/fmicb.2016.02015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
299 Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract 2016;2016:9086581. [PMID: 28070184 DOI: 10.1155/2016/9086581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
300 Ramzy I, Elgarem H, Hamza I, Ghaith D, Elbaz T, Elhosary W, Mostafa G, Elzahry MA. Genetic mutations affecting the first line eradication therapy of helicobacter pylori-infected egyptian patients. Rev Inst Med Trop Sao Paulo. 2016;58:88. [PMID: 27982354 DOI: 10.1590/s1678-9946201658088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
301 Nishida H. Discovery of Vonoprazan Fumarate (TAK-438) as a Novel, Potent and Long-Lasting Potassium-Competitive Acid Blocker. Successful Drug Discovery 2016. [DOI: 10.1002/9783527800315.ch10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
302 Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. American Journal of Gastroenterology 2016;111:1736-42. [DOI: 10.1038/ajg.2016.443] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
303 Ferenc S, Gnus J, Kościelna M, Kinda M, Yarka A, Stewart L, Witkiewicz W. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter 2017;22. [PMID: 27879042 DOI: 10.1111/hel.12365] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
304 Wong EH, Ng CG, Chua EG, Tay AC, Peters F, Marshall BJ, Ho B, Goh KL, Vadivelu J, Loke MF. Comparative Genomics Revealed Multiple Helicobacter pylori Genes Associated with Biofilm Formation In Vitro. PLoS One. 2016;11:e0166835. [PMID: 27870886 DOI: 10.1371/journal.pone.0166835] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
305 Brennan DE, Omorogbe J, Hussey M, Tighe D, Holleran G, O’Morain C, Smith SM, McNamara D. Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples. World J Gastroenterol 2016; 22(41): 9214-9221 [PMID: 27895408 DOI: 10.3748/wjg.v22.i41.9214] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
306 Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scandinavian Journal of Gastroenterology 2017;52:238-41. [DOI: 10.1080/00365521.2016.1250157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
307 Karaca RO, Kalkisim S, Altinbas A, Kilincalp S, Yuksel I, Goktas MT, Yasar U, Bozkurt A, Babaoglu MO. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Basic Clin Pharmacol Toxicol 2017;120:199-206. [DOI: 10.1111/bcpt.12667] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
308 Yang X, Tan P, Song L, Lu Z. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. American Journal of Therapeutics 2016;23:e1436-41. [DOI: 10.1097/mjt.0000000000000261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
309 Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388:2355-2365. [PMID: 27769562 DOI: 10.1016/s0140-6736(16)31409-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 13.8] [Reference Citation Analysis]
310 Lü M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016;11:e0163743. [PMID: 27723762 DOI: 10.1371/journal.pone.0163743] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 11.7] [Reference Citation Analysis]
311 Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY. Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations. Gut Liver 2016;10:12-26. [PMID: 26696028 DOI: 10.5009/gnl15091] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
312 Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016;9:845-852. [PMID: 27803739 DOI: 10.1177/1756283x16668093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
313 Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Dig Dis Sci 2016;61:3215-20. [PMID: 27659671 DOI: 10.1007/s10620-016-4305-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
314 Abuhammour A, Dajani A, Nounou M, Zakaria M. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. Arab J Gastroenterol 2016;17:131-6. [PMID: 27665525 DOI: 10.1016/j.ajg.2016.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
315 Ribaldone DG, Saracco G, Pellicano R. Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients". Gastroenterol Res Pract 2016;2016:4760378. [PMID: 27641900 DOI: 10.1155/2016/4760378] [Reference Citation Analysis]
316 Fontes LES, Batista CS, Martimbianco ALC, Zanin CG, Riera R. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
317 Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J, Meira AC, Pinto H, Alves E, Mascarenhas R, Passos R, de Souza JD, Trindade OR, Coelho LG. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol 2016; 22(33): 7587-7594 [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
318 Zhang Y, Wang S, Hu B, Zhao F, Xiang P, Ji D, Chen F, Liu X, Yang F, Wu Y, Kong M, Nan L, Miao Y, Jiang W, Fang Y, Zhang J, Bao Z, Olszewski MA, Zhao H. Direct detection of Helicobacter pylori in biopsy specimens using a high-throughput multiple genetic detection system. Future Microbiol 2016;11:1521-34. [PMID: 27599152 DOI: 10.2217/fmb-2016-0149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
319 Croaker A, King GJ, Pyne JH, Anoopkumar-Dukie S, Liu L. Sanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current Uses. Int J Mol Sci 2016;17:E1414. [PMID: 27618894 DOI: 10.3390/ijms17091414] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
320 Macegoniuk K, Grela E, Palus J, Rudzińska-szostak E, Grabowiecka A, Biernat M, Berlicki Ł. 1,2-Benzisoselenazol-3(2 H )-one Derivatives As a New Class of Bacterial Urease Inhibitors. J Med Chem 2016;59:8125-33. [DOI: 10.1021/acs.jmedchem.6b00986] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 10.2] [Reference Citation Analysis]
321 Adebisi AO, Conway BR. Modification of drug delivery to improve antibiotic targeting to the stomach. Ther Deliv 2015;6:741-62. [PMID: 26149788 DOI: 10.4155/tde.15.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
322 Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine (Baltimore) 2016;95:e2698. [PMID: 26986096 DOI: 10.1097/MD.0000000000002698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
323 Dhar P, Ng GZ, Sutton P. How host regulation of Helicobacter pylori-induced gastritis protects against peptic ulcer disease and gastric cancer. Am J Physiol Gastrointest Liver Physiol 2016;311:G514-20. [PMID: 27469367 DOI: 10.1152/ajpgi.00146.2016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
324 Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016;16:79. [PMID: 27460100 DOI: 10.1186/s12876-016-0490-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
325 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
326 Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis. Medicine (Baltimore). 2016;95:e2750. [PMID: 26886617 DOI: 10.1097/md.0000000000002750] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
327 Haider RB, Brennan DE, Omorogbe J, Holleran G, Hall B, O'Morain C, Breslin N, O'Connor HJ, Smith SM, McNamara D. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol. 2015;27:1265-1269. [PMID: 26287955 DOI: 10.1097/meg.0000000000000457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
328 Puig I, Baylina M, Sánchez-delgado J, López-gongora S, Suarez D, García-iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother 2016;71:2740-53. [DOI: 10.1093/jac/dkw220] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
329 Song ZQ, Zhou LY. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication: EMMB therapy for H. pylori eradication. Journal of Digestive Diseases 2016;17:260-7. [DOI: 10.1111/1751-2980.12334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
330 Kwack W, Lim Y, Lim C, Graham DY. High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea. Gastroenterol Res Pract 2016;2016:1648047. [PMID: 27413365 DOI: 10.1155/2016/1648047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
331 Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Adv Ther 2016;33:1140-57. [DOI: 10.1007/s12325-016-0345-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
332 Wang YH, Lv ZF, Zhong Y, Liu DS, Chen SP, Xie Y. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter. 2017;22. [PMID: 27282442 DOI: 10.1111/hel.12324] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
333 Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence 2016;10:1025-35. [PMID: 27354772 DOI: 10.2147/PPA.S102760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
334 Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication: . European Journal of Gastroenterology & Hepatology 2016;28:676-83. [DOI: 10.1097/meg.0000000000000590] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
335 Choi M, Karunaratne K, Kohen A. Flavin-Dependent Thymidylate Synthase as a New Antibiotic Target. Molecules 2016;21:E654. [PMID: 27213314 DOI: 10.3390/molecules21050654] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
336 Alsohaibani F, Al Ashgar H, Al Kahtani K, Kagevi I, Peedikayil M, Alfadda A, Khan M. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015;21:220-5. [PMID: 26228365 DOI: 10.4103/1319-3767.161647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
337 Chung JW, Han JP, Kim KO, Kim SY, Hong SJ, Kim TH, Kim CW, Kim JS, Kim BW, Bang BW. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. Dig Liver Dis. 2016;48:888-892. [PMID: 27257049 DOI: 10.1016/j.dld.2016.05.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
338 Han R, Lu H, Jiang MW, Tan KW, Peng Z, Hu JL, Fang DC, Lan CH, Wu XL. Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterol Res Pract 2016;2016:8547686. [PMID: 27247569 DOI: 10.1155/2016/8547686] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
339 Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14:577-585. [PMID: 27077447 DOI: 10.1080/14787210.2016.1178065] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
340 Ul-Haq Z, Ashraf S, Al-Majid AM, Barakat A. 3D-QSAR Studies on Barbituric Acid Derivatives as Urease Inhibitors and the Effect of Charges on the Quality of a Model. Int J Mol Sci 2016;17:E657. [PMID: 27144563 DOI: 10.3390/ijms17050657] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
341 Chakravarty R, Hong H, Cai W. Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 2015;16:592-609. [PMID: 25182469 DOI: 10.2174/1389450115666140902125657] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
342 Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. Exp Ther Med 2016;12:3-17. [PMID: 27347010 DOI: 10.3892/etm.2016.3293] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
343 Hong J, Shu X, Liu D, Zhu Y, Xie C, Xie Y, Zhang K, Wang A, Xiong H, Zeng H. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016;71:2280-2285. [PMID: 27107097 DOI: 10.1093/jac/dkw118] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
344 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 457] [Cited by in F6Publishing: 490] [Article Influence: 76.2] [Reference Citation Analysis]
345 Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
346 Dong F, Ji D, Huang R, Zhang F, Huang Y, Xiang P, Kong M, Nan L, Zeng X, Wu Y, Bao Z. Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. Medicine (Baltimore). 2015;94:e2056. [PMID: 26632710 DOI: 10.1097/md.0000000000002056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
347 Song Z, Suo B, Zhang L, Zhou L. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. Helicobacter. 2016;21:462-470. [PMID: 27060292 DOI: 10.1111/hel.12313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
348 Heo J, Jeon SW, Jung JT, Kwon JG, Lee DW, Kim HS, Yang CH, Park JB, Park KS, Cho KB. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. J Gastroenterol Hepatol. 2015;30:1361-1366. [PMID: 25867608 DOI: 10.1111/jgh.12983] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
349 Shaikh T, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. Can J Gastroenterol Hepatol 2016;2016:7321574. [PMID: 27446864 DOI: 10.1155/2016/7321574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
350 Lu C, Sang J, He H, Wan X, Lin Y, Li L, Li Y, Yu C. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 2016;6:23522. [PMID: 26997149 DOI: 10.1038/srep23522] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
351 Kefeli A, Başyigit S, Yeniova AO, Ozkan S, Nazligul Y. Comparison of the efficacy and safety of hybrid and sequential therapies as a first-line regimen for Helicobacter pylori infection in Turkey. Arch Med Sci 2018;14:276-80. [PMID: 29593799 DOI: 10.5114/aoms.2016.58595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
352 Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
353 Fakheri H, Bakhshi Z, Bari Z, Alhooei S. Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure. Middle East J Dig Dis 2016;8:51-6. [PMID: 26933482 DOI: 10.15171/mejdd.2016.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
354 Makhlough A, Fakheri H, Hojati S, Hosseini V, Bari Z. A Comparison between Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Eradication in Patients with Uremia: A Randomized Clinical Trial. Middle East J Dig Dis. 2016;8:39-43. [PMID: 26933480 DOI: 10.15171/mejdd.2016.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
355 Gonçalves IC, Magalhães A, Costa AM, Oliveira JR, Henriques PC, Gomes P, Reis CA, Martins MC. Bacteria-targeted biomaterials: Glycan-coated microspheres to bind Helicobacter pylori. Acta Biomater 2016;33:40-50. [PMID: 26805428 DOI: 10.1016/j.actbio.2016.01.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
356 Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem. Helicobacter. 2016;21:349-363. [PMID: 26822340 DOI: 10.1111/hel.12299] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
357 Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates. Helicobacter. 2016;21:382-388. [PMID: 26809022 DOI: 10.1111/hel.12294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
358 Liu KSH, Wong IOL, Leung WK. Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance. World J Gastroenterol 2016; 22(3): 1311-1320 [PMID: 26811668 DOI: 10.3748/wjg.v22.i3.1311] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
359 Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84. [PMID: 26108005 DOI: 10.1590/0037-8682-0027-2015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
360 Raymond J, Thiberge JM, Dauga C. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. Scand J Gastroenterol. 2016;51:672-678. [PMID: 26784882 DOI: 10.3109/00365521.2015.1132338] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
361 Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Dig Liver Dis. 2016;48:506-511. [PMID: 26847964 DOI: 10.1016/j.dld.2016.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
362 Bang CS, Kim YS, Park SH, Kim JB, Baik GH, Suk KT, Yoon JH, Kim DJ. Additive effect of pronase on the eradication rate of first-line therapy for Helicobacter pylori infection. Gut Liver. 2015;9:340-345. [PMID: 25167799 DOI: 10.5009/gnl13399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
363 Lee JW. Clarithromycin. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_36] [Reference Citation Analysis]
364 Noh HM, Hong SJ, Han JP, Park KW, Lee YN, Lee TH, Ko BM, Lee JS, Lee MS. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. Korean J Gastroenterol 2016;68:260. [DOI: 10.4166/kjg.2016.68.5.260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
365 Kwon YH. Tailored Therapy Based on Antibiotic Resistance. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_45] [Reference Citation Analysis]
366 Sasaki M. Trends in Global Eradication Rates. Helicobacter pylori 2016. [DOI: 10.1007/978-4-431-55705-0_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
367 Molina-infante J, Graham DY. Helicobacter pylori Therapy. Helicobacter pylori Research 2016. [DOI: 10.1007/978-4-431-55936-8_20] [Reference Citation Analysis]
368 Graham DY, Mohammadi M. Synopsis of Antibiotic Treatment. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_40] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
369 Anania C, Celani C, Chiesa C, Pacifico L. Probiotics Usage in Childhood Helicobacter pylori Infection. Probiotics, Prebiotics, and Synbiotics 2016. [DOI: 10.1016/b978-0-12-802189-7.00051-4] [Reference Citation Analysis]
370 Lee JY. Quadruple Therapy. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_42] [Reference Citation Analysis]
371 Lee JY. Triple Therapy. Helicobacter pylori 2016. [DOI: 10.1007/978-981-287-706-2_41] [Reference Citation Analysis]
372 An HJ, Lee NH, Kang C, Song HY, Yang JS, Kim EJ, Seo YH. The Clinical Features andHelicobacter pyloriEradication Therapy in Lymphofollicular Gastritis: A Single Center Experience. Korean J Helicobacter Up Gastrointest Res 2016;16:221. [DOI: 10.7704/kjhugr.2016.16.4.221] [Reference Citation Analysis]
373 Molina-infante J. Quadruple Regimens for Helicobacter pylori Infection. Helicobacter pylori 2016. [DOI: 10.1007/978-4-431-55705-0_15] [Reference Citation Analysis]
374 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol 2015; 21(48): 13432-13437 [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
375 Jung SM, Cheung DY, Kim JI, Kim I, Seong H. Comparing the Efficacy of Concomitant Therapy with Sequential Therapy as the First-Line Therapy of Helicobacter pylori Eradication. Gastroenterol Res Pract 2016;2016:1293649. [PMID: 26823662 DOI: 10.1155/2016/1293649] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
376 Arama SS, Tiliscan C, Negoita C, Croitoru A, Arama V, Mihai CM, Pop F, Garg A. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients. Gastroenterol Res Pract 2016;2016:5061640. [PMID: 26858750 DOI: 10.1155/2016/5061640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
377 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 396] [Cited by in F6Publishing: 427] [Article Influence: 56.6] [Reference Citation Analysis]
378 Lesjak M, Simin N, Orcic D, Franciskovic M, Knezevic P, Beara I, Aleksic V, Svircev E, Buzas K, Mimica-dukic N. Binary and Tertiary Mixtures of Satureja hortensis and Origanum vulgare Essential Oils as Potent Antimicrobial Agents Against Helicobacter pylori: Essential Oil Mixture Against H . pylori. Phytother Res 2016;30:476-84. [DOI: 10.1002/ptr.5552] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
379 Nkuize M, De Wit S, Muls V, Delforge M, Miendje Deyi VY, Cadière GB, Buset M. HIV-Helicobacter pylori Co-Infection: Antibiotic Resistance, Prevalence, and Risk Factors. PLoS One 2015;10:e0145119. [PMID: 26691198 DOI: 10.1371/journal.pone.0145119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
380 Kalkan IH, Sapmaz F, Güliter S, Atasoy P. Severe gastritis decreases success rate of Helicobacter pylori eradication. Wien Klin Wochenschr 2016;128:329-34. [PMID: 26637331 DOI: 10.1007/s00508-015-0896-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
381 Chan CC, Chien NH, Lee CL, Yang YC, Hung CS, Tu TC, Wu CH. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. [PMID: 26635102 DOI: 10.1186/s12876-015-0401-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
382 Wu Z, Hou J, Wang Y, Chai M, Xiong Y, Lu W, Pan J. Preparation and evaluation of amoxicillin loaded dual molecularly imprinted nanoparticles for anti- Helicobacter pylori therapy. International Journal of Pharmaceutics 2015;496:1006-14. [DOI: 10.1016/j.ijpharm.2015.10.065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
383 Ingram RJ, Ragunath K, Atherton JC. Peptic Ulcer Disease. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch56] [Reference Citation Analysis]
384 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
385 Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015;64:1715-20. [PMID: 26338726 DOI: 10.1136/gutjnl-2015-309900] [Cited by in Crossref: 98] [Cited by in F6Publishing: 106] [Article Influence: 14.0] [Reference Citation Analysis]
386 Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, Kwon HJ, Ku KH, Yoo CH, Kim JH. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30:801-807. [PMID: 26552455 DOI: 10.3904/kjim.2015.30.6.801] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
387 Chua EG, Verbrugghe P, Perkins TT, Tay CY. Fucoidans Disrupt Adherence of Helicobacter pylori to AGS Cells In Vitro. Evid Based Complement Alternat Med 2015;2015:120981. [PMID: 26604968 DOI: 10.1155/2015/120981] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
388 Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol 2015; 21(39): 11179-11184 [PMID: 26494972 DOI: 10.3748/wjg.v21.i39.11179] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
389 Shin WG, Lee SW, Baik GH, Huh KC, Lee SI, Chung JW, Jung WT, Park MI, Jung HK, Kim HU. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. Helicobacter. 2016;21:266-278. [PMID: 26470999 DOI: 10.1111/hel.12279] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
390 Cerqueira RM, Correia MR, Vilar H, Manso MC. How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? OBES SURG 2016;26:1163-6. [DOI: 10.1007/s11695-015-1920-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
391 Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Nam RH, Suh JH, Lee JW, Lee DH. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scand J Gastroenterol. 2016;51:270-276. [PMID: 26452405 DOI: 10.3109/00365521.2015.1095352] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
392 Yang L, Hao WW, Li Y, Xu F. Efficacy of different courses of concomitant therapy and bismuth containing quadruple therapy for eradication of Helicobacter pyloriShijie Huaren Xiaohua Zazhi 2015; 23(28): 4589-4594 [DOI: 10.11569/wcjd.v23.i28.4589] [Reference Citation Analysis]
393 Weiner N, Shaoul R. Impact of Age, Gender, and Addition of Probiotics on Treatment Success for Helicobacter pylori in Children. Glob Pediatr Health 2015;2:2333794X15607798. [PMID: 27335981 DOI: 10.1177/2333794X15607798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
394 Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;51:145-151. [PMID: 26435055 DOI: 10.3109/00365521.2015.1079646] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
395 Lamouliatte H, Zerbib F, Fotsing G, Chabrun E, Mégraud F, Cayla R, Cazorla S, Talbi P. La quadrithérapie bismuthée est supérieure au traitement séquentiel pour l’éradication de Helicobacter pylori : résultats d’une étude comparative en routine. Acta Endosc 2015;45:198-202. [DOI: 10.1007/s10190-015-0514-1] [Reference Citation Analysis]
396 Chen KY, Lin TJ, Lin CL, Lee HC, Wang CK, Wu DC. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. World J Gastroenterol 2015; 21(36): 10435-10442 [PMID: 26420970 DOI: 10.3748/wjg.v21.i36.10435] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
397 Lee JW, Kim N, Nam RH, Kim JM, Park JY, Lee SM, Kim JS, Lee DH, Jung HC. High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones. Antimicrob Agents Chemother 2015;59:7629-36. [PMID: 26416863 DOI: 10.1128/AAC.01467-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
398 Kocazeybek B, Tokman HB. Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review. Helicobacter. 2016;21:251-260. [PMID: 26395982 DOI: 10.1111/hel.12272] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
399 Yoon K, Kim N, Nam RH, Suh JH, Lee S, Kim JM, Lee JY, Kwon YH, Choi YJ, Yoon H. Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea. J Gastroenterol Hepatol. 2015;30:490-495. [PMID: 25363555 DOI: 10.1111/jgh.12839] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
400 Debowski AW, Sehnal M, Liao T, Stubbs KA, Marshall BJ, Benghezal M. Expansion of the tetracycline-dependent regulation toolbox for Helicobacter pylori. Appl Environ Microbiol 2015;81:7969-80. [PMID: 26362986 DOI: 10.1128/AEM.02191-15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
401 Agréus L, Talley NJ, Jones M. Value of the “Test & Treat” Strategy for Uninvestigated Dyspepsia at Low Prevalence Rates of Helicobacter pylori in the Population. Helicobacter 2016;21:186-91. [DOI: 10.1111/hel.12267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
402 Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16:2307-2317. [PMID: 26330278 DOI: 10.1517/14656566.2015.1084503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
403 Kuipers EJ. When Is Endoscopic Follow-up Appropriate After Helicobacter pylori Eradication Therapy? Gastroenterology Clinics of North America 2015;44:597-608. [DOI: 10.1016/j.gtc.2015.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
404 Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, Li P, Ye QL, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. [PMID: 26290044 DOI: 10.1136/bmj.h4052] [Cited by in Crossref: 94] [Cited by in F6Publishing: 103] [Article Influence: 13.4] [Reference Citation Analysis]
405 Yadav S, Karthikeyan S. Structural and biochemical characterization of GTP cyclohydrolase II from Helicobacter pylori reveals its redox dependent catalytic activity. J Struct Biol 2015;192:100-15. [PMID: 26272484 DOI: 10.1016/j.jsb.2015.08.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
406 Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19:1637-1650. [PMID: 26245678 DOI: 10.1517/14728222.2015.1073261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
407 Draeger S, Wüppenhorst N, Kist M, Glocker EO. Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing. J Antimicrob Chemother 2015;70:3141-5. [PMID: 26245638 DOI: 10.1093/jac/dkv223] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
408 Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015;42:922-933. [PMID: 26238858 DOI: 10.1111/apt.13346] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
409 Eng NF, Ybazeta G, Chapman K, Fraleigh NL, Letto R, Altman E, Diaz-Mitoma F. Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario. Can J Infect Dis Med Microbiol 2015;26:137-44. [PMID: 26236355 DOI: 10.1155/2015/853287] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
410 Sung JK. Diagnosis and Treatment of &lt;i&gt;Helicobacter Pylori&lt;/i&gt; Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
411 Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol 2016;40:124-31. [PMID: 26186880 DOI: 10.1016/j.clinre.2015.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
412 Ren L, Lu H, Li HY, Zhu LY, Xu XQ, Gu LY, Ge ZZ, Li XB. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. J Dig Dis. 2014;15:622-627. [PMID: 25205201 DOI: 10.1111/1751-2980.12186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
413 Schwarzer A, Bontems P, Urruzuno P, Kalach N, Iwanczak B, Roma-giannikou E, Sykora J, Kindermann A, Casswall T, Cadranel S, Koletzko S. Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children. Helicobacter 2016;21:106-13. [DOI: 10.1111/hel.12240] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
414 Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380-1384. [PMID: 25229983 DOI: 10.1097/meg.0000000000000197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
415 Ermis F, Tasci ES. Current Helicobacter pylori treatment in 2014. World J Methodol 2015; 5(2): 101-107 [PMID: 26140276 DOI: 10.5662/wjm.v5.i2.101] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
416 Zhou L, Zhang J, Song Z, He L, Li Y, Qian J, Bai P, Xue Y, Wang Y, Lin S. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Helicobacter. 2016;21:91-99. [PMID: 26104022 DOI: 10.1111/hel.12242] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
417 Dolapcioglu C, Sayiner M, Akkus EE, Kural A, Dolapcioglu H, Dabak R, Ahishali E. First-line Bismuth-containing Five-day Concomitant Quintuple Therapy for Helicobacter Pylori Eradication. Helicobacter 2016;21:100-5. [PMID: 26103789 DOI: 10.1111/hel.12241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
418 McMahon BJ, Bruce MG, Koch A, Goodman KJ, Tsukanov V, Mulvad G, Borresen ML, Sacco F, Barrett D, Westby S, Parkinson AJ. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect 2016;144:225-33. [PMID: 26094936 DOI: 10.1017/S0950268815001181] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
419 Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am 2015;44:519-35. [PMID: 26314666 DOI: 10.1016/j.gtc.2015.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
420 López-Góngora S, Puig I, Calvet X, Villoria A, Baylina M, Muñoz N, Sanchez-Delgado J, Suarez D, García-Hernando V, Gisbert JP. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 2015;70:2447-55. [PMID: 26078393 DOI: 10.1093/jac/dkv155] [Cited by in Crossref: 92] [Cited by in F6Publishing: 96] [Article Influence: 13.1] [Reference Citation Analysis]
421 Kutluk G, Tutar E, Bayrak A, Volkan B, Akyon Y, Celikel C, Ertem D. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? Eur J Gastroenterol Hepatol. 2014;26:1202-1208. [PMID: 25171023 DOI: 10.1097/meg.0000000000000190] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
422 Modak JK, Liu YC, Machuca MA, Supuran CT, Roujeinikova A. Structural Basis for the Inhibition of Helicobacter pylori α-Carbonic Anhydrase by Sulfonamides. PLoS One 2015;10:e0127149. [PMID: 26010545 DOI: 10.1371/journal.pone.0127149] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
423 Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2015;42:131-41. [PMID: 26011564 DOI: 10.1111/apt.13259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
424 Jheng GH, Wu IC, Shih HY, Wu MC, Kuo FC, Hu HM, Liu CJ, Hsu WH, Hu CT, Bair MJ, Kuo CH, Wu DC, Hsu PI. Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. Biomed Res Int 2015;2015:163960. [PMID: 26090383 DOI: 10.1155/2015/163960] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
425 Nie J, Yuan XM, Wu WM. Efficacy of bismuth containing quadruple therapy in eradication of Helicobacter pylori in patients with peptic ulcer. Shijie Huaren Xiaohua Zazhi 2015; 23(14): 2346-2350 [DOI: 10.11569/wcjd.v23.i14.2346] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
426 Cosme A, Lizasoan J, Montes M, Tamayo E, Alonso H, Mendarte U, Martos M, Fernández-Reyes M, Saraqueta C, Bujanda L. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. Helicobacter 2016;21:29-34. [PMID: 25982426 DOI: 10.1111/hel.12231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
427 Eisig JN, Navarro-rodriguez T, Teixeira ACS, Silva FM, Mattar R, Chinzon D, Haro C, Diniz MA, Moraes-filho JP, Fass R, Barbuti RC. Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial. Gastroenterology Research and Practice 2015;2015:1-5. [DOI: 10.1155/2015/818043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
428 Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 2015;28:337-418. [PMID: 25788514 DOI: 10.1128/CMR.00117-14] [Cited by in Crossref: 812] [Cited by in F6Publishing: 841] [Article Influence: 116.0] [Reference Citation Analysis]
429 Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia. Saudi J Gastroenterol 2014;20:212-8. [PMID: 25038206 DOI: 10.4103/1319-3767.136935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
430 Lockrey G, Lim L. Peptic Ulcer Disease in Older People. Journal of Pharmacy Practice and Research 2015;41:58-61. [DOI: 10.1002/j.2055-2335.2011.tb00069.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
431 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
432 Hwang JJ, Lee DH, Kang KK, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy. World J Gastroenterol 2015; 21(13): 3936-3943 [PMID: 25852279 DOI: 10.3748/wjg.v21.i13.3936] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
433 Cuadrado-Lavín A, Salcines-Caviedes JR, Diaz-Perez A, Carrascosa MF, Ochagavía M, Fernandez-Forcelledo JL, Cobo M, Fernández-Gil P, Ayestarán B, Sánchez B. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother. 2015;70:2376-2381. [PMID: 25855760 DOI: 10.1093/jac/dkv089] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
434 Yang J, Dai LX, Pan X, Wang H, Li B, Zhu J, Li MY, Shi XL, Wang BN. Protection against Helicobacter pylori infection in BALB/c mice by oral administration of multi-epitope vaccine of CTB-UreI-UreB. Pathog Dis. 2015;73:pii ftv026. [PMID: 25846576 DOI: 10.1093/femspd/ftv026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
435 Borase HP, Salunkhe RB, Patil CD, Suryawanshi RK, Salunke BK, Wagh ND, Patil SV. Innovative approach for urease inhibition by Ficus carica extract-fabricated silver nanoparticles: An in vitro study. Biotechnol Appl Biochem 2015;62:780-4. [PMID: 25560197 DOI: 10.1002/bab.1341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
436 Smith SM, Haider RB, O'Connor H, McNamara D, O'Morain C. Practical treatment of Helicobacter pylori: a balanced view in changing times. Eur J Gastroenterol Hepatol. 2014;26:819-825. [PMID: 24892516 DOI: 10.1097/meg.0000000000000130] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
437 Binh TT, Suzuki R, Kwon DH, Yamaoka Y. Complete Genome Sequence of a Metronidazole-Resistant Helicobacter pylori Strain. Genome Announc 2015;3:e00051-15. [PMID: 25767223 DOI: 10.1128/genomeA.00051-15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
438 Faiza N, Fatima J, Samra S, Muhammad ZA, Hira N, Laiba R, Aisha S, Huma N, Nayab L. A review on Helicobacter pylori infection and treatment. Afr J Pharm Pharmacol 2015;9:274-278. [DOI: 10.5897/ajpp2013.3574] [Reference Citation Analysis]
439 Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study. World J Gastroenterol 2015; 21(9): 2786-2792 [PMID: 25759550 DOI: 10.3748/wjg.v21.i9.2786] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 80] [Article Influence: 10.7] [Reference Citation Analysis]
440 Seo SI, Kim SJ, Kim HS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY. Is There Any Difference in the Eradication Rate of Helicobacter pylori Infection According to the Endoscopic Stage of Peptic Ulcer Disease? Helicobacter 2015;20:424-30. [DOI: 10.1111/hel.12221] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
441 Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol 2014;45:1439-48. [PMID: 25763052 DOI: 10.1590/s1517-83822014000400039] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
442 Chitapanarux T, Thongsawat S, Pisespongsa P, Leerapun A, Kijdamrongthum P. Effect of Bifidobacterium longum on PPI-based triple therapy for eradication of Helicobacter pylori: A randomized, double-blind placebo-controlled study. Journal of Functional Foods 2015;13:289-94. [DOI: 10.1016/j.jff.2015.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
443 Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: Is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol 2015; 21(8): 2522-2533 [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
444 Nijevitch AA, Idrisov B, Akhmadeeva EN, Graham DY. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des 2014;20:4510-6. [PMID: 24180406 DOI: 10.2174/13816128113196660728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
445 Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol 2015;15:23. [PMID: 25886722 DOI: 10.1186/s12876-015-0245-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
446 Binh TT, Suzuki R, Trang TT, Kwon DH, Yamaoka Y. Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing. Antimicrob Agents Chemother. 2015;59:2343-2348. [PMID: 25645832 DOI: 10.1128/aac.04852-14] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
447 Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9. [PMID: 25776067 DOI: 10.1111/apt.13069] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
448 Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015; 21(1): 351-359 [PMID: 25574111 DOI: 10.3748/wjg.v21.i1.351] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
449 Kim SH, Jung JT, Kwon JG, Kim EY, Kang SM, Song JE. Trend in the Eradication Rates ofHelicobacter pyloriInfection in the Last 8 Years in Daegu: A Single Center Experience. Korean J Helicobacter Up Gastrointest Res 2015;15:236. [DOI: 10.7704/kjhugr.2015.15.4.236] [Reference Citation Analysis]
450 Choi KD. Current Trends of Helicobacter pylori Eradication in Korea. Korean J Helicobacter Up Gastrointest Res 2015;15:147. [DOI: 10.7704/kjhugr.2015.15.3.147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
451 Hao S, Wang B, Wang Y. Researching the dose ratio in a controlled release multiple-drug delivery system: using combination therapy with porous microparticles for the treatment of Helicobacter pylori infection. J Mater Chem B 2015;3:417-31. [DOI: 10.1039/c4tb01127a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
452 Le X, Gu Q, Xu J. Identifying MurI uncompetitive inhibitors by correlating decomposed binding energies with bioactivity. RSC Adv 2015;5:40536-45. [DOI: 10.1039/c5ra03079j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
453 Shakya S, Zhang G, Hu H, Li Z. &lt;i&gt;Lactobacillus&lt;/i&gt; GG Supplementation on Anti-&lt;i&gt;Helicobacter pylori&lt;/i&gt; Therapy-Related Side Effects and Eradication Rates: A Meta-Analysis. OJIM 2015;05:96-105. [DOI: 10.4236/ojim.2015.54014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
454 Labenz J, Schumacher G. Entzündliche Erkrankungen des Magens und Duodenums. Viszeralmedizin 2015. [DOI: 10.1007/978-3-642-14301-4_20] [Reference Citation Analysis]
455 Kim JS. The Optimal Second-line Rescue Therapy after Failure of Non-bismuth Quadruple Treatments. Korean J Helicobacter Up Gastrointest Res 2015;15:145. [DOI: 10.7704/kjhugr.2015.15.2.145] [Reference Citation Analysis]
456 Doffou AS, Attia KA, Bathaix MFY, Bangoura AD, Kissy-anzouan YH, Kouamé HD, Mahassadi KA, N’da KJ, Kouyaté M, Assi C, N’dri-yoman AT. The &lt;i&gt;Helicobacter pylori&lt;/i&gt; Eradication Rate in a High Prevalence Area (West Africa): Three Triple Therapy Comparative Study. OJGas 2015;05:200-206. [DOI: 10.4236/ojgas.2015.512030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
457 Kim JH. Recent Update on Third-line Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res 2015;15:89. [DOI: 10.7704/kjhugr.2015.15.2.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
458 Safavi M, Shams-Ardakani M, Foroumadi A. Medicinal plants in the treatment of Helicobacter pylori infections. Pharm Biol. 2015;53:939-960. [PMID: 25430849 DOI: 10.3109/13880209.2014.952837] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
459 Weiss AA. Helicobacter pyloriTreatment and Eradication. Mount Sinai Expert Guides 2014. [DOI: 10.1002/9781118932759.ch18] [Reference Citation Analysis]
460 Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015;47:114-118. [PMID: 25467826 DOI: 10.1016/j.dld.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
461 Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895-905.e5. [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036] [Cited by in Crossref: 105] [Cited by in F6Publishing: 116] [Article Influence: 13.1] [Reference Citation Analysis]
462 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
463 Xie C, Lu NH. Review: clinical management of Helicobacter pylori infection in China. Helicobacter. 2015;20:1-10. [PMID: 25382801 DOI: 10.1111/hel.12178] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 7.6] [Reference Citation Analysis]
464 Montes M, Villalon FN, Eizaguirre FJ, Delgado M, Muñoz-Seca IM, Fernández-Reyes M, Pérez-Trallero E. Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. Helicobacter 2015;20:169-75. [PMID: 25382231 DOI: 10.1111/hel.12187] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
465 Marín AC, Mcnicholl AG, Savarino V, Calvet X, Leontiadis GI, Fischbach L, Yuan Y, Gisbert JP; Cochrane Upper GI and Pancreatic Diseases Group. Optimum second-line regimens for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
466 Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:179-88. [PMID: 25360301 DOI: 10.1177/2050640614530919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
467 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis. World J Gastroenterol 2014; 20(40): 14973-14985 [PMID: 25356059 DOI: 10.3748/wjg.v20.i40.14973] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
468 Modolo LV, de Souza AX, Horta LP, Araujo DP, de Fátima Â. An overview on the potential of natural products as ureases inhibitors: A review. J Adv Res 2015;6:35-44. [PMID: 25685542 DOI: 10.1016/j.jare.2014.09.001] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 15.4] [Reference Citation Analysis]
469 Schulz TR, McBryde ES, Leder K, Biggs BA. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One 2014;9:e108610. [PMID: 25268809 DOI: 10.1371/journal.pone.0108610] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
470 Song Z, Zhang J, He L, Chen M, Hou X, Li Z, Zhou L. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014;46:1077-1081. [PMID: 25220697 DOI: 10.1016/j.dld.2014.08.038] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
471 Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol. 2014;63:158-170. [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
472 Kang BK, Park SM, Kim BW. [New therapeutic strategies against Helicobacter pylori]. Korean J Gastroenterol 2014;63:146-50. [PMID: 24651587 DOI: 10.4166/kjg.2014.63.3.146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
473 Jo Y. [Decreased eradication rates of Helicobacter pylori and problem solving]. Korean J Gastroenterol 2014;63:63-5. [PMID: 24707549 DOI: 10.4166/kjg.2014.63.2.63] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
474 Morse AL, Goodman KJ, Munday R, Chang HJ, Morse JW, Keelan M, Geary J, Sander Vv; CANHelp Working Group. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. Can J Gastroenterol 2013;27:701-6. [PMID: 24340314 DOI: 10.1155/2013/143047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
475 Ntagirabiri R, Harerimana S, Makuraza F, Ndirahisha E, Kaze H, Moibeni A. Helicobacter pylori au Burundi : première évaluation de la prévalence en endoscopie et de l’éradication. J Afr Hepato Gastroenterol 2014;8:217-22. [DOI: 10.1007/s12157-014-0567-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
476 Emami MH, Zobeiri M, Rahimi H, Arjomandi F, Daghagzadeh H, Adibi P, Hashemi J. N-acetyl cysteine as an adjunct to standard anti-Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial. Adv Biomed Res 2014;3:189. [PMID: 25298958 DOI: 10.4103/2277-9175.140403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
477 Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-5. [PMID: 24295850 DOI: 10.1136/gutjnl-2013-306120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
478 Xie Y, Zhu Y, Zhou H, Lu ZF, Yang Z, Shu X, Guo XB, Fan HZ, Tang JH, Zeng XP, Wen JB, Li XQ, He XX, Ma JH, Liu DS, Huang CB, Xu NJ, Wang NR, Lu NH. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol 2014; 20(32): 11415-11421 [PMID: 25170230 DOI: 10.3748/wjg.v20.i32.11415] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
479 Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus. World J Gastroenterol 2014; 20(31): 10969-10983 [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
480 Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
481 Fakheri H, Bari Z, Aarabi M, Malekzadeh R. Helicobacter pylori eradication in West Asia: A review. World J Gastroenterol 2014; 20(30): 10355-10367 [PMID: 25132752 DOI: 10.3748/wjg.v20.i30.10355] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
482 Heo J, Jeon SW, Jung JT, Kwon JG, Kim EY, Lee DW, Seo HE, Ha CY, Kim HJ, Kim ES, Park KS, Cho KB, Lee SH, Jang BI; Daegu-Gyeongbuk Gastrointestinal Study Group. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis. 2014;46:980-984. [PMID: 25132282 DOI: 10.1016/j.dld.2014.07.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
483 Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20(29): 9912-9921 [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
484 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
485 Chehter EZ. Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not? GHOA 2014;1. [DOI: 10.15406/ghoa.2014.01.00011] [Reference Citation Analysis]
486 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clin Microbiol Infect 2014;20:1127-33. [PMID: 24890952 DOI: 10.1111/1469-0691.12701] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
487 Zhou Y, Xu QH, Zhou ZJ, Dong YB. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradicating Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2014; 22(19): 2809-2812 [DOI: 10.11569/wcjd.v22.i19.2809] [Reference Citation Analysis]
488 Lee JW, Kim N, Kim JM, Nam RH, Kim JY, Lee JY, Lee DH, Jung HC. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. Scand J Gastroenterol. 2014;49:917-924. [PMID: 24988873 DOI: 10.3109/00365521.2014.896409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
489 Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication. Diagnostic Microbiology and Infectious Disease 2014;79:358-61. [DOI: 10.1016/j.diagmicrobio.2014.03.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
490 Lee JW, Kim N, Nam RH, Park JH, Choi YJ, Kim JM, Kim JS, Jung HC. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. Scand J Gastroenterol. 2014;49:1058-1067. [PMID: 24957849 DOI: 10.3109/00365521.2014.894117] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
491 Chung WC, Jung SH, Oh JH, Kim TH, Cheung DY, Kim BW, Kim SS, Kim JI, Sin EY. Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection. World J Gastroenterol 2014; 20(21): 6547-6553 [PMID: 24914376 DOI: 10.3748/wjg.v20.i21.6547] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
492 Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
493 Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014; 20(18): 5252-5262 [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
494 Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014;19:372-381. [PMID: 24826809 DOI: 10.1111/hel.12136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
495 Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol 2014; 20(18): 5283-5293 [PMID: 24833858 DOI: 10.3748/wjg.v20.i18.5283] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 103] [Article Influence: 12.3] [Reference Citation Analysis]
496 Malfertheiner P, Venerito M, Selgrad M. Helicobacter pylori infection: selected aspects in clinical management. Curr Opin Gastroenterol. 2013;29:669-675. [PMID: 24100726 DOI: 10.1097/mog.0b013e328365d443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
497 Gong EJ, Yun SC, Jung HY, Lim H, Choi KS, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, Kim JH. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci. 2014;29:704-713. [PMID: 24851029 DOI: 10.3346/jkms.2014.29.5.704] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
498 Hinc K, Stasiłojć M, Piątek I, Peszyńska-Sularz G, Isticato R, Ricca E, Obuchowski M, Iwanicki A. Mucosal adjuvant activity of IL-2 presenting spores of bacillus subtilis in a murine model of Helicobacter pylori vaccination. PLoS One 2014;9:e95187. [PMID: 24743850 DOI: 10.1371/journal.pone.0095187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
499 Zhang S, Desrosiers J, Aponte-Pieras JR, DaSilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss SF. Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods. PLoS One 2014;9:e94974. [PMID: 24740005 DOI: 10.1371/journal.pone.0094974] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
500 Hao S, Wang Y, Wang B. Sinking-magnetic microparticles prepared by the electrospray method for enhanced gastric antimicrobial delivery. Mol Pharm 2014;11:1640-50. [PMID: 24679346 DOI: 10.1021/mp5000339] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
501 Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. [PMID: 24800203 DOI: 10.1155/2014/124607] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
502 Makobongo MO, Gilbreath JJ, Merrell DS. Nontraditional therapies to treat Helicobacter pylori infection. J Microbiol. 2014;52:259-272. [PMID: 24682990 DOI: 10.1007/s12275-014-3603-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
503 Wu JY, Wang SSW, Lee YC, Yamaoka Y, Graham DY, Jan CM, Wang WM, Wu DC. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. World J Gastroenterol 2014; 20(12): 3343-3349 [PMID: 24695835 DOI: 10.3748/wjg.v20.i12.3343] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
504 Zhou L, Zhang J, Chen M, Hou X, Li Z, Song Z, He L, Lin S. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109:535-541. [PMID: 24642580 DOI: 10.1038/ajg.2014.26] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
505 Hussain SA, Hamid S. Helicobacter pylori in humans: Where are we now? Adv Biomed Res 2014;3:63. [PMID: 24627871 DOI: 10.4103/2277-9175.125844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
506 Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014;19:207-213. [PMID: 24612093 DOI: 10.1111/hel.12113] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
507 Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485-495. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 108] [Cited by in F6Publishing: 116] [Article Influence: 13.5] [Reference Citation Analysis]
508 De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol. 2014;63:748-752. [PMID: 24586031 DOI: 10.1099/jmm.0.072322-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
509 Kao CY, Lee AY, Huang AH, Song PY, Yang YJ, Sheu SM, Chang WL, Sheu BS, Wu JJ. Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment. Infect Genet Evol. 2014;23:196-202. [PMID: 24576534 DOI: 10.1016/j.meegid.2014.02.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
510 Fallone CA, Barkun AN, Szilagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013;27:397-402. [PMID: 23862170 DOI: 10.1155/2013/801915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
511 Ayala G, Escobedo-Hinojosa WI, Cruz-Herrera CFL, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20(6): 1450-1469 [PMID: 24587621 DOI: 10.3748/wjg.v20.i6.1450] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 89] [Article Influence: 10.8] [Reference Citation Analysis]
512 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
513 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. Helicobacter 2014;19:90-7. [PMID: 24506175 DOI: 10.1111/hel.12106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
514 Hoseinpoor R, Mousavi Gargari SL, Rasooli I, Rajabibazl M, Shahi B. Functional Mutations in and Characterization of VHH Against Helicobacter pylori Urease. Appl Biochem Biotechnol 2014;172:3079-91. [DOI: 10.1007/s12010-014-0750-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
515 McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP; Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-9. [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820] [Cited by in Crossref: 92] [Cited by in F6Publishing: 103] [Article Influence: 11.5] [Reference Citation Analysis]
516 Pacifico L, Osborn JF, Bonci E, Romaggioli S, Baldini R, Chiesa C. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol 2014; 20(3): 673-683 [PMID: 24574741 DOI: 10.3748/wjg.v20.i3.673] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
517 Kanizaj TF, Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014; 20(3): 699-705 [PMID: 24574743 DOI: 10.3748/wjg.v20.i3.699] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
518 Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645-648. [PMID: 23403439 DOI: 10.1097/mpg.0b013e31828b3669] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
519 Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013;73:815-24. [PMID: 23625272 DOI: 10.1007/s40265-013-0053-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
520 Hao S, Wang Y, Wang B, Zou Q, Zeng H, Chen X, Liu X, Liu J, Yu S. A novel gastroretentive porous microparticle for anti-Helicobacter pylori therapy: preparation, in vitro and in vivo evaluation. Int J Pharm. 2014;463:10-21. [PMID: 24406672 DOI: 10.1016/j.ijpharm.2013.12.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
521 Sierra F, Forero J, Rey M. Ideal treatment for Helicobacter pylori: A systematic review. Revista de Gastroenterología de México (English Edition) 2014;79:28-49. [DOI: 10.1016/j.rgmxen.2014.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
522 Sykes JE, Marks SL. Gastric Helicobacter-like Infections. Canine and Feline Infectious Diseases. Elsevier; 2014. pp. 465-73. [DOI: 10.1016/b978-1-4377-0795-3.00049-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
523 Seo SI, Kim HY. Helicobacter pylori-related Peptic Ulcer Disease. Korean J Med 2014;86:655. [DOI: 10.3904/kjm.2014.86.6.655] [Reference Citation Analysis]
524 Kim SY, Park DK, Kwon KA, Kim KO, Kim YJ, Chung JW. Ten Day Concomitant Therapy Is Superior to Ten Day Sequential Therapy for Helicobacter pylori Eradication. Korean J Gastroenterol 2014;64:260. [DOI: 10.4166/kjg.2014.64.5.260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
525 Jung YS, Lee SH, Park CS, Oh MJ, Kim KO, Jang BI, Jeon SW, Jung MK, Park KS, Kim ES, Cho KB, Jung JT, Kwon JG, Kim EY, Kim WJ, Yang CH. Trends in the Eradication Rates of Helicobacter pylori Infection in Daegu and Gyeongsangbuk-do, Korea: Multicenter Study over 13 Years. Korean J Gastroenterol 2014;63:82. [DOI: 10.4166/kjg.2014.63.2.82] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
526 Sierra F, Forero JD, Rey M. [Ideal treatment for Helicobacter pylori: a systematic review]. Rev Gastroenterol Mex 2014;79:28-49. [PMID: 24365458 DOI: 10.1016/j.rgmx.2013.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
527 Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167-172. [PMID: 24656156 DOI: 10.1016/j.kjms.2013.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
528 De Francesco V, Zullo A, Giorgio F, Saracino I, Zaccaro C, Hassan C, Ierardi E, Di Leo A, Fiorini G, Castelli V. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol. 2014;63:453-457. [PMID: 24344205 DOI: 10.1099/jmm.0.067942-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
529 Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 83] [Article Influence: 4.6] [Reference Citation Analysis]
530 Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014;8:21-28. [PMID: 24410470 DOI: 10.1586/17474124.2014.859522] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
531 Trifan A, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Dorobat C, Grigore L, Stanciu C. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol 2013; 19(42): 7476-7479 [PMID: 24259981 DOI: 10.3748/wjg.v19.i42.7476] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
532 Tonkic A, Tonkic M, Brnic D, Novak A, Puljiz Z, Simunic M. Time trends of primary antibiotic resistance of Helicobacter pylori isolates in Southern Croatia. Journal of Chemotherapy 2013;24:182-4. [DOI: 10.1179/1973947812y.0000000001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
533 Sierra MS, Hastings EV, Goodman KJ. What do we know about benefits of H. pylori treatment in childhood? Gut Microbes. 2013;4:549-567. [PMID: 24280768 DOI: 10.4161/gmic.27000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
534 Mouly C, Chati R, Scotté M, Regimbeau J. Therapeutic management of perforated gastro-duodenal ulcer: Literature review. Journal of Visceral Surgery 2013;150:333-40. [DOI: 10.1016/j.jviscsurg.2013.07.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
535 Mouly C, Chati R, Scotté M, Regimbeau J. Prise en charge de l’ulcère gastroduodénal perforé : revue de littérature. Journal de Chirurgie Viscérale 2013;150:356-364. [DOI: 10.1016/j.jchirv.2013.06.003] [Reference Citation Analysis]
536 Modak JK, Revitt-Mills SA, Roujeinikova A. Cloning, purification and preliminary crystallographic analysis of the complex of Helicobacter pylori α-carbonic anhydrase with acetazolamide. Acta Crystallogr Sect F Struct Biol Cryst Commun 2013;69:1252-5. [PMID: 24192362 DOI: 10.1107/S1744309113026146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
537 Tai WC, Chiu CH, Liang CM, Chang KC, Kuo CM, Chiu YC, Wu KL, Hu ML, Chou YP, Chiou SS, Chiu KW, Kuo CH, Hu TH, Lin MT, Chuah SK. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan. Gastroenterol Res Pract. 2013;2013:932478. [PMID: 24235968 DOI: 10.1155/2013/932478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
538 Dib J Jr, Alvarez B, Mendez L, Cruz ME. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Arab J Gastroenterol. 2013;14:123-125. [PMID: 24206741 DOI: 10.1016/j.ajg.2013.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
539 Huang J, Zhou L, Geng L, Yang M, Xu XW, Ding ZL, Mao M, Wang ZL, Li ZL, Li DY, Gong ST. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. Aliment Pharmacol Ther. 2013;38:1230-1235. [PMID: 24117692 DOI: 10.1111/apt.12516] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
540 Siao D, Somsouk M. Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med. 2014;29:520-528. [PMID: 24065381 DOI: 10.1007/s11606-013-2630-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
541 Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol. 2013;13:138. [PMID: 24050512 DOI: 10.1186/1471-230x-13-138] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
542 Thamphiwatana S, Fu V, Zhu J, Lu D, Gao W, Zhang L. Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery. Langmuir 2013;29:12228-33. [PMID: 23987129 DOI: 10.1021/la402695c] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 10.1] [Reference Citation Analysis]
543 Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC; Taiwan Acid-Related Disease (TARD) Study Group. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter. 2014;19:74-79. [PMID: 24033865 DOI: 10.1111/hel.12085] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
544 Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PMID: 23926315 DOI: 10.1136/bmj.f4587] [Cited by in Crossref: 175] [Cited by in F6Publishing: 193] [Article Influence: 19.4] [Reference Citation Analysis]
545 Vedham V, Divi RL, Starks VL, Verma M. Multiple infections and cancer: implications in epidemiology. Technol Cancer Res Treat 2014;13:177-94. [PMID: 23919392 DOI: 10.7785/tcrt.2012.500366] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
546 Ang TL, Wang L, Ang D, Chiam P, Fock KM, Teo EK. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J Dig Dis 2013;14:100-4. [PMID: 23253473 DOI: 10.1111/1751-2980.12024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
547 Chason RD, Reisch JS, Rockey DC. More favorable outcomes with peptic ulcer bleeding due to Helicobacter pylori. Am J Med. 2013;126:811-818.e1. [PMID: 23830535 DOI: 10.1016/j.amjmed.2013.02.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
548 Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
549 Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
550 Onal IK, Gokcan H, Benzer E, Bilir G, Oztas E. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. Clin Res Hepatol Gastroenterol. 2013;37:642-646. [PMID: 23796974 DOI: 10.1016/j.clinre.2013.05.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
551 Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D’Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol. 2013;37:647-650. [PMID: 23747131 DOI: 10.1016/j.clinre.2013.04.003] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
552 Bastos J, Peleteiro B, Barros R, Alves L, Severo M, de Fátima Pina M, Pinto H, Carvalho S, Marinho A, Guimarães JT, Azevedo A, La Vecchia C, Barros H, Lunet N. Sociodemographic Determinants of Prevalence and Incidence of Helicobacter pylori Infection in Portuguese Adults. Helicobacter 2013;18:413-22. [DOI: 10.1111/hel.12061] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
553 Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18:459-467. [PMID: 23714140 DOI: 10.1111/hel.12062] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
554 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228-013-1524-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
555 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
556 Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J. 2013;54:1-4. [PMID: 23661891 DOI: 10.4103/0300-1652.108884] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
557 Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2013;37:1165-1171. [PMID: 23656465 DOI: 10.1111/apt.12329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
558 Every AL. Key host–pathogen interactions for designing novel interventions against Helicobacter pylori. Trends in Microbiology 2013;21:253-9. [DOI: 10.1016/j.tim.2013.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
559 Molina-Infante J, Gisbert JP. [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. Gastroenterol Hepatol. 2013;36:375-381. [PMID: 23623461 DOI: 10.1016/j.gastrohep.2013.02.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
560 Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
561 Schmitt BH, Regner M, Mangold KA, Thomson RB, Kaul KL. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. Mod Pathol. 2013;26:1222-1227. [PMID: 23579617 DOI: 10.1038/modpathol.2013.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
562 Correia M, Michel V, Osório H, El Ghachi M, Bonis M, Boneca IG, De Reuse H, Matos AA, Lenormand P, Seruca R, Figueiredo C, Machado JC, Touati E. Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid.PLoS One. 2013;8:e60657. [PMID: 23577140 DOI: 10.1371/journal.pone.0060657] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
563 Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121-128.e1. [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050] [Cited by in Crossref: 138] [Cited by in F6Publishing: 153] [Article Influence: 15.3] [Reference Citation Analysis]
564 Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens M, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clinical Microbiology and Infection 2013;19:379-83. [DOI: 10.1111/j.1469-0691.2012.03844.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
565 Moon DI, Shin EH, Oh HG, Oh JS, Hong S, Chung Y, Kim O. Usefulness of a Helicobacter pylori stool antigen test for diagnosing H. pylori infected C57BL/6 mice. Lab Anim Res. 2013;29:27-32. [PMID: 23573105 DOI: 10.5625/lar.2013.29.1.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
566 Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.e1. [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008] [Cited by in Crossref: 99] [Cited by in F6Publishing: 109] [Article Influence: 11.0] [Reference Citation Analysis]
567 Shin WG. New Trend of Helicobacter pylori Treatment. Korean J Med 2013;85:586. [DOI: 10.3904/kjm.2013.85.6.586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
568 Hong J, Yang HR. Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children. Pediatr Gastroenterol Hepatol Nutr. 2012;15:237-242. [PMID: 24010093 DOI: 10.5223/pghn.2012.15.4.237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
569 El-Omar EM. Iron deficiency and Helicobacter pylori-induced gastric cancer: too little, too bad. J Clin Invest 2013;123:113-4. [PMID: 23257355 DOI: 10.1172/JCI67200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
570 den Hollander WJ, Kuipers EJ. Commentary: simvastatin as the key to improving H. pylori eradication rates? Aliment Pharmacol Ther 2012;36:493; author reply 494. [PMID: 22860610 DOI: 10.1111/j.1365-2036.2012.05195.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
571 Strugatsky D, McNulty R, Munson K, Chen CK, Soltis SM, Sachs G, Luecke H. Structure of the proton-gated urea channel from the gastric pathogen Helicobacter pylori. Nature. 2013;493:255-258. [PMID: 23222544 DOI: 10.1038/nature11684] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
572 Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG, Kim HY, Baik IH, Jang HJ. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18(45): 6628-6634 [PMID: 23236238 DOI: 10.3748/wjg.v18.i45.6628] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
573 Francesco VD, Zullo A, Hassan C. Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients? World J Gastrointest Pharmacol Ther 2012; 3(6): 103-104 [PMID: 23494655 DOI: 10.4292/wjgpt.v3.i6.103] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
574 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Sociedad Española de Medicina de Familia y Comunitaria. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Gastroenterol Hepatol 2012;35:725.e1-38. [PMID: 23186826 DOI: 10.1016/j.gastrohep.2012.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
575 den Hollander WJ, Kuipers EJ. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012;13:2625-2636. [PMID: 23167300 DOI: 10.1517/14656566.2012.747510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
576 Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi A, Benajah DA. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study. Clin Res Hepatol Gastroenterol. 2013;37:416-421. [PMID: 23168228 DOI: 10.1016/j.clinre.2012.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
577 Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter. 2013;18:129-134. [PMID: 23121338 DOI: 10.1111/hel.12017] [Cited by in Crossref: 73] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
578 Heineman J, Bubenik S, McClave S, Martindale R. Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? Curr Gastroenterol Rep. 2012;14:343-348. [PMID: 22763792 DOI: 10.1007/s11894-012-0274-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
579 Jeong MH, Chung JW, Lee SJ, Ha M, Jeong SH, Na S, Na BS, Park SK, Kim YJ, Kwon KA. [Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori]. Korean J Gastroenterol. 2012;59:401-406. [PMID: 22735872 DOI: 10.4166/kjg.2012.59.6.401] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
580 Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, Tamosiunas V, Kupcinskas J, Miciuleviciene J, Kadusevicius E, Berg D, Andersen LP. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. APMIS 2013;121:431-6. [DOI: 10.1111/apm.12012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
581 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Asociación Española de Gastroenterología., Sociedad Española de Medicina de Familia y Comunitaria., Centro Cochrane Iberoamericano. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Aten Primaria 2012;44:727.e1-727.e38. [PMID: 23036729 DOI: 10.1016/j.aprim.2012.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
582 Cerqueira RM, Correia MR, Fernandes CD, Vilar H, Manso MC. Cumulative Helicobacter pylori Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery. OBES SURG 2013;23:145-9. [DOI: 10.1007/s11695-012-0747-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
583 Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter. 2012;17:43-48. [PMID: 22221615 DOI: 10.1111/j.1523-5378.2011.00896.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
584 Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
585 Hosseinzadeh N, Hasani M, Foroumadi A, Nadri H, Emami S, Samadi N, Faramarzi MA, Saniee P, Siavoshi F, Abadian N, Mahmoudjanlou Y, Sakhteman A, Moradi A, Shafiee A. 5-Nitro-heteroarylidene analogs of 2-thiazolylimino-4-thiazolidinones as a novel series of antibacterial agents. Med Chem Res 2013;22:2293-302. [DOI: 10.1007/s00044-012-0224-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
586 Giordano A, Cito L. Advances in gastric cancer prevention. World J Clin Oncol 2012; 3(9): 128-136 [PMID: 23061031 DOI: 10.5306/wjco.v3.i9.128] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
587 Sereni G, Azzolini F, Camellini L, Formisano D, Decembrino F, Iori V, Tioli C, Cavina M, Di Mario F, Bedogni G, Sassatelli R. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. World J Gastroenterol 2012; 18(33): 4542-4548 [PMID: 22969227 DOI: 10.3748/wjg.v18.i33.4542] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
588 Basarab GS, Hill P, Eyermann CJ, Gowravaram M, Käck H, Osimoni E. Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty. Bioorganic & Medicinal Chemistry Letters 2012;22:5600-7. [DOI: 10.1016/j.bmcl.2012.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
589 De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther 2012; 3(4): 68-73 [PMID: 22966485 DOI: 10.4292/wjgpt.v3.i4.68] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
590 Gasparetto M, Pescarin M, Guariso G. Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012;2012:186734. [PMID: 22900197 DOI: 10.5402/2012/186734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
591 Kao SS, Chen WC, Hsu PI, Lai KH, Yu HC, Cheng HH, Peng NJ, Lin CK, Chan HH, Tsai WL. 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan. Gastroenterol Res Pract. 2012;2012:463985. [PMID: 22888337 DOI: 10.1155/2012/463985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
592 Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18:1-2. [PMID: 22249084 DOI: 10.4103/1319-3767.91724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
593 Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol. 2012;18:11-17. [PMID: 22249086 DOI: 10.4103/1319-3767.91729] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
594 Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, Wang HM, Yu HC, Chen WC, Peng NJ. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol. 2012;27:498-503. [PMID: 21871025 DOI: 10.1111/j.1440-1746.2011.06885.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
595 Borlace GN, Keep SJ, Prodoehl MJR, Jones HF, Butler RN, Brooks DA. A role for altered phagosome maturation in the long-term persistence of Helicobacter pylori infection. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012;303:G169-79. [DOI: 10.1152/ajpgi.00320.2011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
596 Wu W, Yang Y, Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract 2012;2012:723183. [PMID: 22829809 DOI: 10.1155/2012/723183] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
597 Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks! J Clin Gastroenterol. 2012;46:259-261. [PMID: 22395061 DOI: 10.1097/mcg.0b013e318247177e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
598 Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
599 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
600 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
601 Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E, Aresti-Zárate S. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012;67:2254-2259. [PMID: 22687889 DOI: 10.1093/jac/dks209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
602 Graham DY, Shiotani A. Which Therapy for Helicobacter pylori Infection. Gastroenterology. 2012;143:10-12. [PMID: 22613622 DOI: 10.1053/j.gastro.2012.05.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
603 Attumi TA, Graham DY. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol. 2012;27:59-61. [PMID: 21793914 DOI: 10.1111/j.1440-1746.2011.06876.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
604 Castro M, Romero C, de Castro A, Vargas J, Medina E, Millán R, Brenes M. Assessment of Helicobacter pylori eradication by virgin olive oil. Helicobacter. 2012;17:305-311. [PMID: 22759331 DOI: 10.1111/j.1523-5378.2012.00949.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
605 O’Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine. 2012;30:3876-3884. [PMID: 22512976 DOI: 10.1016/j.vaccine.2012.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
606 Fakheri H, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter. 2012;17:264-268. [PMID: 22759325 DOI: 10.1111/j.1523-5378.2012.00946.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
607 Isobe H, Nishiyama A, Takano T, Higuchi W, Nakagawa S, Taneike I, Fukushima Y, Yamamoto T. Reduction of overall Helicobacter pylori colonization levels in the stomach of Mongolian gerbil by Lactobacillus johnsonii La1 (LC1) and its in vitro activities against H. pylori motility and adherence. Biosci Biotechnol Biochem. 2012;76:850-852. [PMID: 22484956 DOI: 10.1271/bbb.110921] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
608 Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology. 2012;143:55-61.e1; quize e13-4. [PMID: 22484118 DOI: 10.1053/j.gastro.2012.03.043] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 6.0] [Reference Citation Analysis]
609 Reva I, Takano T, Higuchi W, Iwao Y, Taneike I, Nakagawa S, Ike M, Pererva O, Tarankov A, Agapov M, Rizhkov E, Singur O, Reva G, Potapov V, Yamamoto T. Virulence genotypes and drug resistance of Helicobacter pylori from Vladivostok, Russia: another feature in the Far East: I. Reva et al. Microbiology and Immunology 2012;56:198-202. [DOI: 10.1111/j.1348-0421.2011.00425.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
610 Molina-infante J, Pazos-pacheco C, Vinagre-rodriguez G, Perez-gallardo B, Dueñas-sadornil C, Hernandez-alonso M, Gonzalez-garcia G, Mateos-rodriguez JM, Fernandez-bermejo M, Gisbert JP. Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains: Nonbismuth Quadruple Concomitant Therapy for Helicobacter pylori infection. Helicobacter 2012;17:269-76. [DOI: 10.1111/j.1523-5378.2012.00947.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
611 Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 2012;17:216-223. [PMID: 22515360 DOI: 10.1111/j.1523-5378.2012.00937.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
612 Chang WL, Kao CY, Wu CT, Huang AH, Wu JJ, Yang HB, Cheng HC, Sheu BS. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan. Helicobacter. 2012;17:210-215. [PMID: 22515359 DOI: 10.1111/j.1523-5378.2012.00935.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
613 Garcia-Mazcorro JF, Suchodolski JS, Jones KR, Clark-Price SC, Dowd SE, Minamoto Y, Markel M, Steiner JM, Dossin O. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol Ecol. 2012;80:624-636. [PMID: 22324305 DOI: 10.1111/j.1574-6941.2012.01331.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 8.4] [Reference Citation Analysis]
614 Goh KL, Manikam J, Qua CS. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2012;35:1097-1102. [PMID: 22404486 DOI: 10.1111/j.1365-2036.2012.05054.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
615 Pacifico L, Osborn JF, Anania C, Vaira D, Olivero E, Chiesa C. Review article: bismuth-based therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther 2012. [DOI: 10.1111/j.1365-2036.2012.05055.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
616 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
617 Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012;4:239-243. [PMID: 22358069 DOI: 10.1039/c2mt00180b] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
618 Moya DA, Crissinger KD. Helicobacter Pylori Persistence in Children: Distinguishing Inadequate Treatment, Resistant Organisms, and Reinfection. Curr Gastroenterol Rep 2012;14:236-42. [DOI: 10.1007/s11894-012-0251-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
619 Li Y, Rimbara E, Thirumurthi S, Trespalacios A, Reddy R, Sabounchi S, Attumi TA, Graham DY. Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. J Dig Dis. 2012;13:54-59. [PMID: 22188917 DOI: 10.1111/j.1751-2980.2011.00549.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
620 Sitaraman SV, Friedman LS. Peptic Ulcer Disease. Essentials of Gastroenterology 2012. [DOI: 10.1002/9781119959762.ch3] [Reference Citation Analysis]
621 Graham DY, Trespalacios AA. Treatment of Helicobacter pylori in Latin America. The Lancet 2012;379:408. [DOI: 10.1016/s0140-6736(12)60182-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
622 Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am. 2011;21:613-635. [PMID: 21944414 DOI: 10.1016/j.giec.2011.07.011] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
623 Watson JB, Moss SF. Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol 2011;106:1976-7. [PMID: 22056576 DOI: 10.1038/ajg.2011.309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
624 Kang JH, Lim YJ. Trend for Treatment ofHelicobacter pyloriin Overseas Country. Korean J Helicobacter Up Gastrointest Res 2012;12:224. [DOI: 10.7704/kjhugr.2012.12.4.224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
625 Abu-safieh Y, Yamin H. Sequential and concomitant non-bismuth quadruple therapies are ineffective for &lt;i&gt;H. pylori&lt;/i&gt; eradication in Palestine. A randomized trial. OJGas 2012;02:177-180. [DOI: 10.4236/ojgas.2012.24034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
626 Gaynor D, Griffith DM. The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. Dalton Trans 2012;41:13239. [DOI: 10.1039/c2dt31601c] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
627 Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93. [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
628 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PMID: 21896086 DOI: 10.1111/j.1523-5378.2011.00881.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
629 Njume C, Afolayan AJ, Samie A, Ndip RN. Inhibitory and bactericidal potential of crude acetone extracts of Combretum molle (Combretaceae) on drug-resistant strains of Helicobacter pylori. J Health Popul Nutr 2011;29:438-45. [PMID: 22106749 DOI: 10.3329/jhpn.v29i5.8897] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
630 Kim SY, Jung SW. [Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol 2011;58:67-73. [PMID: 21873820 DOI: 10.4166/kjg.2011.58.2.67] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
631 Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2011;23:865-870. [PMID: 21811161 DOI: 10.1097/meg.0b013e3283496502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
632 Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230-243. [PMID: 21558964 DOI: 10.1097/mpg.0b013e3182227e90] [Cited by in Crossref: 195] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
633 Suzuki H, Matsuzaki J, Hibi T. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication? Expert Rev Clin Pharmacol 2011;4:579-82. [PMID: 22114887 DOI: 10.1586/ecp.11.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
634 Zullo A, Severi C, Vannella L, Hassan C, Sbrozzi-Vanni A, Annibale B. Role of gastritis pattern on Helicobacter pylori eradication. Intern Emerg Med. 2012;7:517-522. [PMID: 22105372 DOI: 10.1007/s11739-011-0730-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
635 Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
636 Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, Song IS. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter. 2011;16:301-310. [PMID: 21762270 DOI: 10.1111/j.1523-5378.2011.00840.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
637 Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, Song HJ, Lee GH, Kim JH. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter. 2011;16:289-294. [PMID: 21762268 DOI: 10.1111/j.1523-5378.2011.00844.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
638 Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011;16:295-300. [PMID: 21762269 DOI: 10.1111/j.1523-5378.2011.00857.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
639 Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 116] [Article Influence: 9.2] [Reference Citation Analysis]
640 Toros AB, Ince AT, Kesici B, Saglam M, Polat Z, Uygun A. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobacter. 2011;16:225-228. [PMID: 21585608 DOI: 10.1111/j.1523-5378.2011.00823.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
641 Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter. 2011;16:241-245. [PMID: 21585611 DOI: 10.1111/j.1523-5378.2011.00841.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
642 Sarkar M, Maganti L, Ghoshal N, Dutta C. In silico quest for putative drug targets in Helicobacter pylori HPAG1: molecular modeling of candidate enzymes from lipopolysaccharide biosynthesis pathway. J Mol Model 2012;18:1855-66. [PMID: 21850571 DOI: 10.1007/s00894-011-1204-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
643 Mazzoleni LE, Francesconi CF, Sander GB. Mass eradication of Helicobacter pylori: feasible and advisable? Lancet 2011;378:462-4. [PMID: 21777975 DOI: 10.1016/S0140-6736(11)61099-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
644 Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507-514. [PMID: 21777974 DOI: 10.1016/s0140-6736(11)60825-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 209] [Article Influence: 16.1] [Reference Citation Analysis]
645 Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2011;45:309-13. [PMID: 21389810 DOI: 10.1097/MCG.0b013e31820ac05e] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
646 Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131-138. [PMID: 21435091 DOI: 10.1111/j.1523-5378.2011.00826.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
647 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 143] [Article Influence: 11.4] [Reference Citation Analysis]
648 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
649 Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011;16:146-152. [PMID: 21435093 DOI: 10.1111/j.1523-5378.2011.00829.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
650 Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol 2011; 2(3): 35-41 [PMID: 21860834 DOI: 10.4291/wjgp.v2.i3.35] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 95] [Article Influence: 7.8] [Reference Citation Analysis]
651 Sokollik C, Jones NL. Helicobacter pylori and Effects on Iron Status in Children: Delineating Causality. Journal of Pediatric Gastroenterology & Nutrition 2011;52:646-647. [DOI: 10.1097/mpg.0b013e318219cbc4] [Reference Citation Analysis]
652 Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2011;66:1847-1852. [PMID: 21632579 DOI: 10.1093/jac/dkr217] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
653 Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785-90. [PMID: 21655065 DOI: 10.3346/jkms.2011.26.6.785] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
654 Tsang YH, Lamb A, Chen LF. New insights into the inactivation of gastric tumor suppressor RUNX3: the role of H. pylori infection. J Cell Biochem 2011;112:381-6. [PMID: 21268057 DOI: 10.1002/jcb.22964] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
655 Monteiro MA, Britton S, Applebee LA, Baqar S. Synthesis and immunogenicity of a Helicobacter pylori lipopolysaccharide-based conjugate. Vaccine 2011;29:3098-102. [DOI: 10.1016/j.vaccine.2011.02.063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
656 Holster IL, den Hoed CM, Kuipers EJ. Peptic Ulcer Bleeding: Endoscopic Diagnosis, Endoscopic Therapy and Pharmacotherapy. Gastrointestinal Bleeding 2011. [DOI: 10.1002/9781444398892.ch4] [Reference Citation Analysis]
657 Buzás GM. [Helicobacter pylori -- 2010]. Orv Hetil 2010;151:2003-10. [PMID: 21106480 DOI: 10.1556/OH.2010.28982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
658 Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med. 2012;23:165-168. [PMID: 22284248 DOI: 10.1016/j.ejim.2011.02.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
659 Lee BH, Kim N. Quadruple or triple therapy to eradicate H pylori. The Lancet 2011;377:877-8. [DOI: 10.1016/s0140-6736(11)60168-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
660 Delchier J-. Quand rechercher Helicobacter pylori et comment l’éradiquer: techniques de recherche, traitements, vérification de l’éradication. Acta Endosc 2011;41:81-82. [DOI: 10.1007/s10190-011-0146-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
661 Malfertheiner P, Bazzoli F, Delchier J, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 2011;377:905-13. [DOI: 10.1016/s0140-6736(11)60020-2] [Cited by in Crossref: 337] [Cited by in F6Publishing: 296] [Article Influence: 30.6] [Reference Citation Analysis]
662 Graham DY, Fischbach LA. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011;183:E506-E508. [PMID: 21343269 DOI: 10.1503/cmaj.101460] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
663 Ayala G, Galván-Portillo M, Chihu L, Fierros G, Sánchez A, Carrillo B, Román A, López-Carrillo L, Silva-Sánchez J. Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico. Microb Drug Resist. 2011;17:149-155. [PMID: 21303219 DOI: 10.1089/mdr.2010.0154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
664 Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88. [DOI: 10.1038/nrgastro.2010.210] [Cited by in Crossref: 131] [Cited by in F6Publishing: 152] [Article Influence: 11.9] [Reference Citation Analysis]
665 Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol. 2010;26:618-623. [PMID: 20827182 DOI: 10.1097/mog.0b013e32833efede] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
666 Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine. 2011;29:2085-2091. [PMID: 21236233 DOI: 10.1016/j.vaccine.2010.12.130] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
667 Varbanova M, Malfertheiner P. Bacterial Load and Degree of Gastric Mucosal Inflammation in <i>Helicobacter pylori</i> Infection. Dig Dis 2011;29:592-9. [DOI: 10.1159/000333260] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
668 Attumi TA, Graham DY. Follow-up testing after treatment of Helicobacter pylori infections: cautions, caveats, and recommendations. Clin Gastroenterol Hepatol 2011;9:373-5. [PMID: 21195791 DOI: 10.1016/j.cgh.2010.12.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 59] [Article Influence: 2.5] [Reference Citation Analysis]
669 Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW, Chian H, Chang SC, Wu MS, Lin JT. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2011;55:1123-1129. [PMID: 21189342 DOI: 10.1128/aac.01131-10] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
670 Berning M, Krasz S, Labenz J, Miehlke S. Moderne Helicobacter-pylori-Therapien in Zeiten zunehmender Antibiotikaresistenz. Med Klin 2010;105:787-791. [DOI: 10.1007/s00063-010-1135-2] [Reference Citation Analysis]
671 Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069-1079. [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x] [Cited by in Crossref: 146] [Cited by in F6Publishing: 165] [Article Influence: 12.2] [Reference Citation Analysis]
672 Kalbina I, Engstrand L, Andersson S, Strid Å. Expression of Helicobacter pylori TonB Protein in Transgenic Arabidopsis thaliana: Toward Production of Vaccine Antigens in Plants: TonB Antigen Production in Transgenic Plants. Helicobacter 2010;15:430-7. [DOI: 10.1111/j.1523-5378.2010.00786.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
673 Griffiths H. Module 5. Pharmacological Management of Dyspepsia. Nurse Prescribing 2010;8:1-10. [DOI: 10.12968/npre.2010.8.9.cpd1] [Reference Citation Analysis]
674 Graham DY. Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol. 2010;8:1032-1036. [PMID: 20656062 DOI: 10.1016/j.cgh.2010.07.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]